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In healthy individuals, coronary arteries dilate in response to sympathetic nervous system (SNS) 
stimulation, whereas in patients with increased cardiovascular disease (CVD) risk this produces a 
truncated dilation. Conversely, in patients with significant disease, these arteries constrict. 
Previous research has demonstrated a correlation between carotid and coronary artery function. 
In addition, a non-invasive measure of carotid artery response (CAR%) has been shown to predict 
adverse events in patients with peripheral arterial disease. In this thesis, these findings were 
extended to investigate the effect of blood pressure (BP) increase caused by the Cold Pressor 
Test (CPT) as a driver of CAR%. CAR% was then also investigated as a means to predict risk in 
patients with central arterial disease undergoing Coronary Artery Bypass Graft (CABG) surgery.  
Methods. The (CPT), a sympathetic nervous system stimulus (SNS) using cold water, was used to 
investigate carotid artery response to an SNS stimulus in two studies. The first investigated CPT 
alongside continuous blood pressure measurement. The second examined CAR% in patients with 
CVD undergoing CABG, with a 30-day follow-up period.  
Results. Study one: The timing of peak CAR% was significantly later than peak MAP. There was 
no significant difference in CAR% when participants are separated by MAP response. There was 
no significant difference in MAP in “dilation” vs “constriction” groups. Study two: There was a 
weak inverse correlation between CAR% and EuroSCORE II. Neither EuroSCORE II nor CAR% alone 
predicted risk. There may be a trend towards a marginal improvement in predictive capacity 
when CAR% is combined with EuroSCORE II. Although this did not predict risk. 
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Discussion. Study one: This study provided evidence that CAR% is not significantly driven by 
increase in MAP throughout the CPT. In addition, it further supports the validity of CAR% as a 
surrogate of endothelial function. Study two: Alone, neither EuroSCORE II nor CAR% were 
predictors of risk. Combined, the two measures demonstrated marginal increased predictive 
capacity. This study suggests that CAR% may improve the predictive capacity of established 
prediction tools. This cannot be tested conclusively due to the low number of adverse events.   
Future Work: This thesis highlighted future areas for research including regulation of CAR%, 
areas for further technological and practical development and areas of potential clinical 
integration, namely in the identification and monitoring of endothelial function alongside 
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1. Chapter 1: Introduction 
The central aim of this thesis is to investigate a novel measure of carotid artery endothelial 
function as a surrogate of vascular health. This test is investigated in both healthy participants 
and in patients with coronary artery disease (CAD) undergoing cardiac surgery. 
The thesis is presented in seven chapters. The first chapter provides a general introduction to the 
thesis.  
In the second chapter, the background to the importance of endothelial function, endothelial 
dysfunction and the physiological implication of the endothelium in arterial health are discussed. 
Current methods of measuring endothelial function, including both invasive and non-invasive 
measures of endothelial function are described. The direct and indirect measures of coronary 
artery endothelial function are also discussed. Together, this provides the basis for the thesis 
whereby carotid artery response (CAR%) may be uniquely placed to offer an insight into coronary 
artery endothelial function.  
The third chapter details the methodology employed within this thesis, focusing on the use of 
the cold pressor test (CPT) as a method to stimulate the sympathetic nervous system (SNS) 
response, alongside the use of carotid artery ultrasound as a tool to investigate carotid artery 
diameter. 
 The fourth chapter outlines the statistical analyses performed, including the justification for the 
analysis, the decision-making process and any limitations and considerations with these 
statistical measures. 
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The fifth chapter describes study one, where the relationship between blood pressure (and 
therefore transmural pressure) and carotid artery response in healthy middle-aged individuals 
was investigated. The extent to which transmural pressure affects carotid artery diameter in 
response to sympathetic stimulation is currently unknown. This is key as the CPT was employed 
to investigate endothelial function as a surrogate of vascular health.  
The sixth chapter described study two. In this, CAR% was investigated in pre-operative patients 
undergoing Coronary Artery Bypass Graft Surgery (CABG) combined with Valve Surgery. This was 
used to investigate the relationship between CAR% and current established methods to predict 
risk. The relationship between CAR% and adverse events (AE) was also investigated to investigate 
if CAR% was predictive of AEs in this group. The CAR% may offer a non-invasive method to 
investigate carotid artery response as a surrogate of coronary artery function in surgical patients. 
Coronary artery endothelial function has previously been demonstrated to predict disease 
progression and outcomes in patients with established cardiovascular disease (CVD).  
The seventh and final chapter provides a discussion of the future work required to fully 
understand the regulation of CAR%. It also highlighted potential areas for further development 
in order to improve the accuracy and reliability of CAR% as a measure of endothelial function. It 
also discusses the potential clinical implications of CAR% and how it could be incorporated into 
clinical practice, namely CAR% as a method to easily identify endothelial dysfunction. This may 
be applied to improve perioperative risk prediction. The CAR% may also be used to quantify 
endothelial dysfunction and therefore offer a target for treatment which aims to improve 
endothelial function in clinical groups.  
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Diagram 1) A schematic representation of chapters contained in this thesis.   
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2. Chapter 2: Background 
2.1. Chapter introduction 
This first chapter introduces the process of atherosclerosis, coronary artery disease as well as 
CABG surgery as a treatment for coronary artery disease. This also outlines current methods of 
risk prediction. This then further discusses endothelial function, current techniques in 
investigating endothelial function and the current literature investigating endothelial function as 
a method to predict risk in coronary artery disease patients. Finally, this chapter discusses the 
limitations in current methods used to investigate endothelial function and explores the use of 
CAR as a method to quantify endothelial function and predict risk in patients undergoing CABG 
surgery.  
2.2. Coronary Artery Disease 
Cardiovascular disease (CVD) is an umbrella term that describes disease of the heart and blood 
vessels, and remains the world’s leading cause of morbidity and mortality (1). CVD accounts for 
approximately 17.7 million deaths world-wide each year, or approximately 31% of all deaths (2). 
Coronary Artery Disease (CAD) is a sub-type of CVD. Coronary artery disease is disease of the 
blood vessels which supply blood to the heart muscle (myocardium). Despite improvements in 
clinical management, and an associated reduction in CVD-related mortality (3), the incidence of 
CVD continues to rise (3). An ageing population, and an increase in prevalence of risk factors in 
younger adults (e.g. obesity, diabetes and hypertension) are likely to contribute to this trend (4). 
Coronary Artery Disease has a profound impact on both individuals and their families. CAD has 
been associated with a significant decrease in quality of life with a progressive decrease in quality 
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of life. This includes both disability and symptom-associated quality of life (5, 6) and a resultant 
significant decrease in mental wellbeing and increase in mental health issues (5, 6) . As well as a 
significant burden on the individual, CAD has a significant societal impact. The 5-year cost of a 
cardiovascular disease in high-risk patients is £23,393 and lifetime cost of £116,888. The total 
cost of CVD-related healthcare costs in England is estimated to be £7.4 billion per year with an 
estimated cost to the wider economy of £15.8 billion per year (7). This therefore means that 
coronary artery disease and cardiovascular disease more broadly have a huge impact for the 
individual, their families and society as a whole.  
Coronary Artery Bypass Graft Surgery 
A common treatment option for CAD is Coronary Artery Bypass Graft (CABG) surgery, with over 
800,000 operations undertaken world-wide each year (8). Approximately half of which are 
performed in North America and one quarter performed in Northern Europe (8). CABG surgery is 
an important treatment option offered to patients with significant coronary artery disease on the 
grounds of both symptom relief and prognostic benefit (9) .  
In CABG surgery, flow-limiting lesions are first identified using angiography or cardiac MRI.  The 
operation is typically performed through a mid-sternal incision. During the operation, potential 
targets are sought and identified distal to the flow-limiting lesion (distal anastomosis). A graft 
(conduit) is then taken from elsewhere within the body. These are typically the internal thoracic 
artery or gastro-epipolic artery although this is less commonly used. The use of these arteries do 
not require proximal anastomosis. The saphenous vein may also be harvested and used, although 
this requires both distal and proximal anastomosis. In both cases, these are used to bypass the 
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flow-limiting lesions thereby restoring blood flow to ischemic segments of myocardium.  This can 
be used to restore blood flow in all of the major coronary arteries, depending upon clinical need. 
This is typically performed in the arrested heart, whilst blood oxygenation and circulation is 
managed by cardiopulmonary bypass. A smaller number of specialist “off-pump” CABG 
procedures are also undertaken in the absence of circulatory arrest.  
Although CABG surgery is a common treatment for CAD, it is associated with significant risk. 
Cumulative short-term risk of operative mortality in isolated CABG surgery is approximately 2.5% 
(10). The longer-term survival in these patients reduced significantly with 5 year survival-, 15 year 
survival-, 25 year survival -, and 35 year survival -, being 86% ± 0.3%, 48% ± 0.5%, 19% ± 0.6%, 
and 7% ± 1.2% respectively (10). The National Adult Cardiac Surgery report investigates morbidity 
and mortality data within the UK over the last 3 years between 1st April 2015 and 31st of March 
2018 (National Adult Cardiac Surgery Audit (NACSA) dataset (version 5.1.0)). This is a UK-specific 
dataset. In 2017/18 there were 32,295 operations undertaken. The mortality rate of isolated 
CABG surgery is approximately 1-2%. The 5, 10 and 15 year mortality in isolated CABG surgery 
between 1999 and 2017 in the UK is 9.2%, 23.5% and 35.6% respectively(11). CABG surgery is 
performed mostly in isolation. However, CABG surgery is also performed in combination with 
other cardiac and non-cardiac surgeries. CABG surgery alongside valve surgery is the most 
common type of combined CABG surgery. The combination of CABG combined with valve surgery 
is associated with a further increase risk of mortality (12). This makes CABG surgery a commonly 
undertaken surgical intervention with significant operative and post-operative risk. Although 
clinical knowledge and operative ability continue to improve, the increase in age and 
comorbidities mean that an increased number of higher-risk operations are being undertaken. 
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This increase in the number of higher risk increasingly complex surgeries highlights the 
requirement to accurately risk stratify patients perioperatively (4).  
Risk Prediction in Coronary Artery Disease and CABG Surgery 
 
Traditionally, predicting future development of CAD and cardiovascular events in CAD patients 
was based on the evaluation of (non)modifiable risk factors, such as age, gender and family 
history of premature CAD. Alongside modifiable risk factors including blood pressure, cholesterol, 
body weight, and glucose homeostasis (13). These risk factors are associated with development 
of cardiovascular disease, disease progression in patients with established CAD and AEs in 
patients undergoing surgical intervention (14). Although these risk factors have been associated 
with increased risk in large scale studies, the precise mechanisms are poorly understood. The 
impact of traditional risk factors on atherosclerosis may at least partly be explained through their 
direct effects on the endothelium. For example, elevated cholesterol, high blood pressure, 
smoking, ageing and obesity are all associated with an increased risk of atherosclerosis (15, 16). 
This is typified by endothelial dysfunction. Endothelial dysfunction also precedes atherosclerosis.  
Molecular mechanisms of CAD 
It is thought that at least in part, CVD risk factors negatively affect endothelial function through 
an increase in ROS. The molecular mechanisms and consequences aren’t completely understood. 
However, some of the mechanisms and consequences have been investigated. The 
consequences can be broadly categorised in to dysfunction affecting eNOS, a reduction in NO 
bioavailability and abnormal responsiveness of VSMC’s to NO.  
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Dysfunction of eNOS.  
A significant cause of endothelial dysfunction is associated with a dysfunction in eNOS activity. 
These are briefly outlined below. This is reviewed more extensively in previously published 
articles (17, 18) .  
Reduced Substrate Activity 
L-arginine is the key precursor to NO. In healthy adults, this can be synthesized de-novo from L-
citruline. When there is a reduction in the availability of both L-arginine and L-citruline, this can 
contribute to a reduction in bioavailability of NO. The acute supplementation of L-arginine can 
curtail endothelial dysfunction, although this benefit may not be seen chronically (17, 19). The 
increase of endothelial arginases associated with aging, diabetes or hypertension competes with 
eNOS for L-arginine thereby reducing bioavailability of NO (20-22) .  
Reduced cofactor availability 
A key cofactor in NO production is BH4 from sepiaterin. If there are low circulating levels of BH4 
or if there is an increase in oxidation of the precursor, BH2 (23). This is associated with a reduction 
in NO bioavailability. The reduction in BH4 or increased oxidation of BH2 is associated with 
diabetes mellitus (24), prolonged exposure to aldosterone or cortisol associated with 
hypertension (25), in chronic inflammation (26) or in post-menopausal women (27) . Importantly, 
supplementation with exogenous BH4 improves endothelial function in patients with BH4-
deficient (23, 28).  
Increased Endogenous Inhibitors 
Asypometric dimethylarginine (ADMA) preferentially displaces an L-arginine precursor thereby 
inhibiting NO production. The increase in ADMA can be accelerated by increased oxidized stress 
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augmented by levels of oxidized and carbamylated LDL. The increase in endogenous inhibitors 
thereby reduce NO production(17). 
Reduced Protein Presence 
The reduction in gene expression encoding eNOS results in a reduction in NO production. CVD 
risk factors including aging, diabetes mellitus, or hypertension result in reduction in the presence 
of proteins associated with NO production (17). These risk factors cause decreased protein 
presence first through the activation of tumour necrosis factor-a causing and translation of 
elongation factor 1-a thereby destabilizing eNOS mRNA. Second through increased presence of 
micro-RNA-155 which destabilizes eNOS mRNA. Third by diminished endogenous antioxidant 
enzymes (catalases) which inhibit activator protein-1 thereby reducing eNOS transcription. 
Fourth increased levels of oxidized-LDL recruiting myocardin-related transcription factor-A to the 
nucleus thereby repressing eNOS gene expression (17, 18). 
Reduced Protein Dimerization 
The dimetric structure of eNOS is essential for its function. There is an increase in 
monomerization of eNOS observed with aging, diabetes mellitus, hypoxia, hyperlipidemia and 
increased oxidative stress. These risk factors are associated with S-nitrosylation at Cys94- and 
Cys99- thereby disrupting the dimetric structure of eNOS thereby reducing NO production (17, 
29).  
Reduced NO Bioavailability 
As well as a reduction in NO production, there is also a reduction in NO bioavailability. The 
increased presence of superoxide anions with an exaggerated formation of peroxynitrite. This is 
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the major factor accelerating the disposition of endothelium-derived NO. As well as reducing NO 
bioavailability, peroxynitrite also has deleterious effects on cell function (18, 30). The blunting of 
NO-mediated response is observed in obesity, diabetes mellitus and hypertension.  
Abnormal Responsiveness of Vascular Smooth Muscle to NO 
As well as abnormalities in the production or bioavailability of NO, there is also an alteration in 
the responsiveness of SMC’s to NO. This can be broadly categorized in to reduced vasodilatory 
response or a paradoxical vasoconstrictive response (18).  
Reduced Vasodilatory Response 
As well as reductions in endothelial-mediated dilation, resulting in dysfunction in vasodilation, 
there can also be dysfunction in the context of a normally functioning endothelium. This reduced 
responsiveness to vasodilatory stimuli can be as a result of a number of distinct mechanisms such 
as. 1) A reduction in the b-subunit of sGC associated with an increased oxidative stress caused by 
aging, hypertension, or diabetes mellitus. 2) A decreased responsiveness to endothelium-derived 
NO caused by an increased expression of phosphodiesterases. These accelerate the breakdown 
of cGMP, reducing expression of PKG (eg in aging and hypertension) or reducing expression of 
calcium-gated potassium channels. The net effect is a reduction in hyperpolarization of VSMC’s 
as seen in aging, diabetes mellitus, hypertension and obesity. 
In summary, a common mechanism by which traditional risk factors increase cardiovascular risk 
and increased operative risk in CABG surgery may be through their effect on the endothelium 
(31). One potential pathway is related to an overproduction of Reactive Oxygen Species (ROS) or 
increased oxidative stress (32, 33). This contributes to a reduction in NO bioavailability and 
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promotes cell damage. It has also been recognized that (low-grade) inflammation plays a key role 
in the development and progression of atherosclerosis and subsequent CAD (34). This is 
summarized in Figure 1. Although traditional risk factor analysis is key in risk stratification, the 
degree to which individual risk factors affect endothelial function is not fully understood. 
Similarly, the protective effects of exercise and dietary supplementation are not incorporated in 
to current risk stratification tools (14). This highlights the importance of directly measuring 
vasomotion as a surrogate of endothelial function, and therefore vascular health in these patient 
groups. This would allow a move away from epidemiological-derived risk stratification tools to a 
personalized approach to risk stratification.  
The most commonly utilized tool in the UK is the EuroSCORE II tool (35). This was first developed 
in 1999 with a subsequent major update in 2011. This tool collects 17 items around the clinical 
status of the patient, state of the heart and operation undertaken and then uses logistic 
regression analysis to calculate the predicted mortality rate (35) . The EuroSCORE II tool is also 
used to risk-adjust national cardiac surgery outcome data within the UK (35).   
Endothelial Function and Risk Prediction 
Coronary artery health has also been suggested as a means to predict future CAD (14). A common 
method of measuring systemic coronary vascular health is through measuring endothelial 
structure and/or function (14). The endothelium plays a central role in vascular health and is 
demonstrated to represent a key step in the initiation and development of atherosclerosis. 
Located between the circulating blood and the vessel wall, the endothelium fulfills a key role in 
signal transduction in response to various hemodynamic stimuli, such as shear stress and wall 
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strain (36) and also contributes to vascular health through the paracrine production of vasoactive 
substances (37). The key role of the endothelium in the pathophysiological mechanism of CAD is 
reinforced by the observation that endothelial dysfunction precedes the development of 
atherosclerosis (38-41), and that measures of coronary artery endothelial function independently 
predict future CAD (42).  
Several techniques are employed to examine endothelial function and vascular structure 
including Flow Mediated Dilatation (FMD) and carotid artery Inter-Medial Thickening (cIMT) 
measurement. These methodologies are summarized in Table 1 below. Due to ease of access and 
their correlation with coronary artery vascular function, these techniques have become common 
in scientific research (43). The most extensively investigated is FMD. Importantly, brachial FMD 
has previously been demonstrated to correlate with CAD severity (44), and has been 
demonstrated to be a prognostic predictor in CAD (45, 46).  One potential limitation of FMD is 
that peripheral arteries show key differences in regulation of vascular tone and anatomy in 
comparison to coronary arteries (47). This may be why FMD is not yet commonly utilized in 
clinical practice (48, 49). Techniques utilized to investigate endothelial function are discussed 
further below. When compared to peripheral arteries, the carotid artery is an easily accessible 
central artery that is similar in anatomical structure and vasomotor control to coronary arteries 
(50). The carotid artery may represent a unique opportunity to asses an easily accessible artery 
with structural and functional characteristics similar to that of central arteries including the 
coronary arteries.  
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Table 1) A summary table of both invasive and non-invasive measures of endothelial function. 
Adapted from Schindler et al (2005), Hays et al (2010), Flammer et al (2012) and Van Mil et al 
(2018) (51-54) 
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2.3. Endothelial Function and Atherosclerosis 
The vascular system is lined by the endothelium; a single layer of cells on the inner surface of all 
vessels. Although the endothelium was first thought of as a simple layer of cells, landmark studies 
have demonstrated that the endothelium fulfils various important actions (55, 56). Primarily, it 
provides a semi-permeable barrier between the constituents of the circulating blood and the 
inner surface of the vessel. This allows the transport of blood-borne cells and macro-molecules 
across the endothelium, controlled through transport vesicles (e.g. caveolae, vesiculo-vacuolar 
organelles) and cell-cell junctions (18). The endothelium also has a key function in its ability to 
regulate vascular tone through the autocrine and paracrine production of vasoactive substances 
(18). The most important vasodilator produced by the endothelium is nitric oxide (NO).  This is a 
gas with a short half-life of 6-30 seconds within the vessel wall and is produced through the 
oxidation of L-arginine to L-citrulline. This reaction is catalysed by NO-synthase with cofactors, 
including tetrahydrobiopterin and nicotinamide adenine dinucleotide phosphate (NADPH). The 
enzyme endothelial Nitric Oxide Synthase (eNOS) is the predominant enzyme responsible for NO 
production within the endothelium. Subsequently, NO diffuses to vascular smooth muscle cells 
(vSMC) and activates guanylate cyclase. This causes an increase in intracellular cyclic guanosine 
monophosphate (cGMP), leading to relaxation of smooth muscle cells (SMC’s) and vasodilation 
(57, 58). Importantly, NO also exerts inhibitory effects on platelet aggregation, leukocyte 
adhesion and VSMC migration and proliferation. Through these pleiotropic effects, production of 
NO contributes to protection against atherosclerosis and cardiovascular disease (18). The 
complex molecular process of NO production in endothelial function and in dysfunctional 
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endothelial cells are reviewed extensively elsewhere (18). This is summarized in figure 1. Taken 
from Vanhoutte et al (2016) (18). 
 
 
Figure 1) Role of the endothelium in nitric oxide production in both a healthy endothelial cell 
and in endothelial dysfunction. Taken from (18) with permission. 
 
The process of atherosclerosis is complex and is well documented elsewhere. (16, 59) The 
relationship between endothelial dysfunction and atherosclerosis is summarized in Figure 2 (60). 
The impact of traditional risk factors on atherosclerosis may at least partly, be explained through 
their direct effects on the endothelium. For example, elevated cholesterol, high blood pressure, 
smoking, ageing and obesity are all associated with an increased risk of atherosclerosis (15, 16).  
A common mechanism by which traditional risk factors increase cardiovascular risk may be 
through their effect on the endothelium (31). One potential pathway is related to an 
overproduction of Reactive Oxygen Species or increased oxidative stress (32, 33). This 
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contributes to a reduction in NO bioavailability and promotes cell damage. It has also been 
recognized that (low-grade) inflammation plays a key role in the development and progression 
of atherosclerosis and subsequent CAD (34).  
Figure 2) A summary of known and emerging risk factors and the effect on endothelial function 
and dysfunction and the development of atherosclerotic cardiovascular disease. Taken from (60) 
with permission.  
Previous studies have demonstrated that endothelial dysfunction is an independent predictor of, 
and contributor to atherosclerosis (61). Ludmer et al (1986) demonstrated for the first time, 
impaired endothelial function in the presence of atherosclerosis using paradoxical constriction 
to acetylcholine (Ach) infusion in patients with mild-to-moderate CAD (62). Similarly, endothelial 
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dysfunction has been demonstrated in pre-clinical stages of atherosclerosis development using 
procedures involving forearm ACh infusion (63) and brachial artery flow mediated dilatation 
(FMD) (64).  Comparable findings have been presented in subsequent studies (51). This highlights 
the importance of the endothelium in the development of atherosclerosis. 
Coronary Artery Endothelial Function Predicts Future CAD 
The strong evidence around the role of the endothelium in mediating atherosclerosis has driven 
a large field in science, focused on examining whether a measure of coronary artery endothelial 
function can predict future development of CAD. Schachinger (2000) and colleagues were one of 
the first to examine whether coronary artery response to endothelium-dependent dilators such 
as Ach, sympathetic activation, increased blood flow, and endothelium-independent 
nitroglycerin can predict future development of CAD. They found that impaired endothelium-
dependent and -independent coronary responses were independently related to higher 
incidence of CAD events (42). They followed patients up for 7.7 years. They defined adverse 
events as death, cardiovascular death (MI, cerebral infarction, sudden cardiac death), unstable 
angina, CABG, Percutaneous Transluminal Coronary Angioplasty or revascularization of 
peripheral arteries. Similarly, Suwaidi et al. (2000) found that CAD and marked coronary artery 
endothelial dysfunction was associated with an increased risk of developing CAD (65). In this 
latter study, endothelial function was measured using intracoronary infusion of acetylcholine 
along-side coronary artery angiography in 157 patients with mild CAD. They were followed up for 
a period of 28 months. Similarly, Halcox et al. (2002) found that endothelial dysfunction is 
predictive of cardiovascular events in patients with and without established CAD. This was 
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investigated using intracoronary infusion of ACh together with quantitative angiography. They 
included 132 patients with established CAD and 176 participants without cardiovascular disease 
and a 46 +/- 3 month follow-up (66).  They defined adverse events as cardiovascular death, MI, 
unstable angina, and acute ischaemic stroke. Cardiovascular death defined as, death due to MI 
or cerebral infarction. Taken together, this suggests that coronary artery endothelial dysfunction 
is predictive of CAD, independent of the presence of cardiovascular risk factors. 
The prognostic effect of endothelial dysfunction was further demonstrated by Suwaidi et al 
(2000) (52) who found that impaired blood flow in response to SNS stimulation, caused by the 
CPT and measured non-invasively using Positron Emission Tomography, was predictive of 
cardiovascular events in 72 patients undergoing diagnostic cardiac catheterization (52). This 
finding was reinforced by Hays et al (2010) who investigated coronary artery endothelial 
dysfunction using coronary artery magnetic resonance imaging (MRI). Coronary artery MRI 
(cMIRI) was used to assess arterial response during handgrip exercise as a sympathetic stimulus. 
They found marked endothelial dysfunction (i.e. vasoconstriction during handgrip exercise) in 
patients with established CAD. However, the predictive capacity of this has not been investigated 
(53). This demonstrates the key prognostic value of coronary artery endothelial dysfunction in 
CAD risk, and that this can be investigated using both invasive and non-invasive methods. This 
also highlights the ability to examine vascular responses to endothelium (in)dependent 
vasodilators as well as activation of the SNS 
Endothelial Function and Hypertension 
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Chronic raised blood pressure (or hypertension) is a key risk factor for CVD. Hypertension is 
defined as a chronically increased systolic blood pressure above 140mmHg or diastolic blood 
pressure above 90mmHg at sea level  (67). In 2015, it was reported that 1 in 4 adults in England 
had hypertension (67). This was estimated to contribute to 75,000 deaths (67). There is also an 
excess all-cause mortality in uncontrolled hypertensive patients (68). Hypertension, cigarette 
smoking, diabetes mellitus and hypercholesterolemia are all modifiable risk factors associated 
with an increased risk of CAD (69). Importantly, hypertension has the strongest evidence for 
causation of CAD within these modifiable risk factors (69). There is also suggestion that 
biologically normal BP is lower than what has been used in current clinical practice. This may 
mean that current models underestimate the impact hypertension has on CAD risk. As well as 
being a significant predictor of risk of CAD, hypertension has also been demonstrated to predict 
risk of left ventricular hypertrophy, valvular disease, cardiac arrythmias, cerebral stroke and renal 
failure (69, 70). It is thought that the prevalence of hypertension is approximately 30-45% of the 
general population (71). Although hypertension is closely linked to CAD and CVD more broadly, 
hypertension and cardiovascular risk should be interpreted in the context of total cardiovascular 
risk, rather than the presence or absence of hypertension alone. Although the mechanism isn’t 
fully understood, it is thought that hypertension increased cardiovascular disease risk through an 
increase in oxidative stress burden. This is reviewed more extensively on in the “molecular 
mechanisms of coronary artery disease” subheading of this thesis. Hypertension is often 
considered a “silent killer” as individuals with clinically significant hypertension may remain 
asymptomatic (72). Chronic hypertension may be at least in part, caused by a loss of peripheral 
vascular function as well as other mechanisms including alterations in arterial structure and 
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stenosis. Endothelial function has therefore been extensively investigated in the context of 
chronic hypertension. Tsutsui and colleagues (2015) demonstrated a significant increase in blood 
pressure in a neuronal, inducible and endothelial Nitric Oxide Synthase (n/i/eNOS-/-) triple 
knockout mouse model in which all three genes encoding NOS production are non-functioning 
(73). Similarly, Huang et al (2012) demonstrated a 30 mmHg increase in systolic blood pressure 
(BP) in a single eNOS-/- knockout model (74). Significant endothelial dysfunction has also been 
demonstrated in patients with hypertension (75). Dose-response curves to the endothelium-
dependent vasodilator Ach were lower in hypertensive patients than in healthy controls (66). 
However, dose-dependent curves to sodium nitroprusside, an endothelium-independent 
vasodilator working on the vSMC’s, were similar in the two groups. This suggests that the loss of 
ability of the arteries to dilate in hypertensive patients is due to a loss of endothelial function 
rather than VSMC-mediated dilatation (66). Importantly, Perticone et al (2001) demonstrated 
that cardiovascular event rates are higher in hypertensive patients with high-grade endothelial 
dysfunction compared to hypertensive patients with low-grade endothelial dysfunction (76). This 
highlights the importance of endothelial function in both CAD and in the risk of developing 
disease in hypertensive patient
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Use of peripheral and central arteries in risk prediction 
The majority of research in risk prediction using non-invasive imaging has used the peripheral 
arteries, particularly the femoral or radial arteries. These are used as surrogates of coronary 
artery endothelial function. This has been reviewed extensively elsewhere (14). However, there 
are distinct differences in both the structural and functional characteristics in central vs 
peripheral arteries. These are summarized in Figure 3.  
The “elastic” arteries have a high density of elastic fibers, lower SMC’s, a thin tunica adventicia 
and a large tunica media with a large number of elastic and collagen fibrils. The net effect of this 
is the ability of “elastic” arteries to store elastic energy released in diastole to maintain a constant 
blood pressure above 60mmHg (14) . Whereas the “elastic” peripheral arteries have a large 
tunica adventicia, a smaller tunica media with less elastic and collagen fibrils. The elastic 
peripheral arteries also have a large VSMC layer. The net result is an ability to expand and 
contract as required (14). 
A second consideration is in the regulation of vasomotion within both central and peripheral 
arteries. Although it is incompletely understood, it is thought that CAR% is predominantly driven 
by adrenoreceptor and metabolic mechanisms. It is thought that shear stress does not play a 
significant role in carotid artery vasomotion. Whereas, FMD is significantly driven by reactive 
hyperemia affecting endothelial function (49).  
A third consideration in using central vs peripheral arteries as surrogates of coronary artery 
endothelial function is the age-related changes in different artery types (77). It has previously 
been demonstrated that, in central arteries there is an increase in arterial stiffness associated 
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with age and that this is predictive of CVD risk (77). Whereas, age-related peripheral arterial 
stiffening is attenuated. The value of peripheral arterial stiffening in CVD risk prediction is limited. 
Arterial stiffness is an important component of vasomotion independent of a fully functioning 
endothelium (77).  
Taken together, the similarities between the carotid and coronary arteries along with the ease of 
access to the coronary artery through carotid artery ultrasound may mean that the carotid 
arteries are uniquely placed to offer an easy to access central artery with both structural and 
functional similarities to the coronary arteries.  
2.4. Vascular structure in coronary and carotid arteries 
The carotid and coronary arteries are large vessels, often referred to as “elastic” or “conducting” 
arteries. Both arteries transport large volumes of blood away from the left ventricle to perfuse 
vital organs, including the brain (partly supplied by the carotid arteries) and myocardium (fully 
supplied by the coronary arteries). As a result, the walls of both arteries are extremely resilient 
and contain large volumes of elastic fibres. The tunica media of the coronary and carotid arteries 
contain a higher density of elastic fibers and fewer SMCs compared to peripheral, muscular 
arteries (78, 79). These structural characteristics allow elastic arteries to tolerate significant 
pressure changes that occur across the cardiac cycle. The differences in central “elastic” and 
peripheral “muscle” arteries are summarized in Figure 3. During ventricular systole, pressure 
within the vessel rises rapidly and the elastic arteries expand, followed by a reduction in blood 
pressure during ventricular diastole. The elastic fibers recoil to allow the artery to return to their 
original dimensions. This expansion during systole dampens the sudden rise in pressure within 
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the vessels, whilst the recoil during diastole slows the drop in pressure. During this process, 
elastin in the arterial wall stores elastic energy during systole, and this is released during diastole. 
Consequently, although blood is pumped from the heart in a cyclic manner, with large differences 
in systolic and diastolic pressure in the left ventricle, arterial blood pressure in central arteries 
does not fall below 60-80mmHg (50, 80). In addition to the large content of elastic fibrils, the 
tunica media also contain collagen fibrils that form a slack network and provide a physical guard 
against over-distension. As vessels age, the stiffer collagen fibrils increasingly dominate the 
tunica media within arteries, thereby reducing rebound capacity of elastic arteries. This age-
related process contributes to impaired ability to dampen the blood pressure fluctuations 
(contributing to an increased pulse pressure), but may also contribute to the progression of 
atherosclerosis and future development of CAD (81, 82). 
 
Figure 3) Comparison of anatomical characteristics between elastic (e.g. coronary and carotid) 
and muscular (e.g. peripheral) arteries. Elastic arteries have a thin tunica adventitia and a large 
tunica media, containing a large amount of elastic and collagen fibers. Under physiological 
conditions, there are relatively few vascular smooth muscle cells within the tunica media of the 
elastic arteries. Muscular arteries have a larger tunica adventitia with a smaller tunica media with 
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few elastic and collagen fibers, but a large vascular SMC layer. Taken from (14) written as part of 
this PhD. 
 
Regulation of vascular tone in coronary and carotid arteries 
The majority of work examining central artery vascular function is based on knowledge derived 
from research on the coronary arteries. This is largely because manipulation and infusion of 
vasoactive substances – both of which are typical procedures to explore function characteristics 
of arteries, have several limitations when applied to the carotid artery in vivo. For this reason, 
the following section mainly focuses on studies that have examined coronary artery vasomotor 
function. It is thought that the regulation of coronary artery vascular tone is a result of vasoactive 
signals influenced by metabolic, neuronal and local mechanisms. All aimed at matching coronary 
blood supply to oxygen demand. 
Metabolic control of vascular tone 
A key mechanism of controlling vascular tone in coronary arteries is through the metabolic 
influence on vascular diameter. Although the mechanism is not fully understood, it is 
hypothesized that cardiac myocytes produce vasodilatory substances including adenosine, NO, 
prostacyclin, bradykinin and Carbon Dioxide (CO2) in response to myocardial oxygen consumption 
(83). Cardiomyocytes can also produce vasoconstrictive substances including angiotensin II (83). 
These vasodilatory and vasoconstrictive substances are released in direct response to the oxygen 
demand and metabolism of local tissues. This allows for a localized response to an increase or 
decrease in oxygen demand, with the release of vasoactive substances which are directly tied to 
oxygen requirement and products of metabolism including CO2, H+ and lactate (14). Hypoxia can 
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cause dilatation both directly and indirectly. Hypoxia can cause dilatation indirectly through the 
release of vasodilatory metabolites. Direct vasodilation through hypoxia may be mediated 
though the release of tissue metabolites. The formation of CO2 during increased oxygen demand 
readily diffuses from parenchymal cells to vSMC’s where it causes dilatation. Similarly, hydrogen 
ions also increase during hypoxia, thereby causing a decrease in pH and vasodilation. Similarly, 
lactic acid produced during anaerobic respiration also causes vasodilation through its effect on 
local pH. 
Sympathetic nervous system-mediated control of vascular tone 
The SNS importantly contributes to the regulation of vascular tone in central arteries, including 
the carotid and coronary arteries. Feigl et al (1975) demonstrated that, in the absence of 
myocardial metabolism, a significant change was present in coronary sinus oxygen tension during 
sympathetic stimulation (84). The contribution of adrenergic receptors in mediating coronary 
perfusion was subsequently confirmed by Mohrman et al (1978) who found that α-
adrenoreceptor blockade caused a decrease in coronary oxygen uptake (85). In a study in cardiac 
transplant patients, both denervation and regional re-innervation of cardiac segments were 
studied simultaneously. They demonstrated increases in coronary flow in response to 
sympathetic stimulation were larger in re-innervated segments compared to denervated 
segments (86). This finding suggests that coronary flow is regulated to a greater extent by 
adrenergic mechanisms than via metabolic regulation during sympathetic stimulation. This is key 
to our study as the carotid artery response is a predominantly NO-mediated mechanism (15, 87). 
It is challenging to study these factors independently, therefore it remains unclear to what extent 
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the metabolic and adrenergic components interact and contribute to coronary vasomotion 
during sympathetic activation (88) 
Coronary responses to sympathetic stimulation are highly dependent on both the integrity (89-
91) and function (92) of the endothelium. The importance of the endothelium in this response is 
in part explained through the presence of adrenoreceptors on both the endothelium and SMC. 
These respond to regional and systemic sympathetic stimuli. For example, local release of 
norepinephrine from adrenergic nerve terminals in the coronary arteries (abluminal release) and 
release of catecholamines from the adrenal glands into the circulation during sympathetic stress 
or physical exercise. These all influence coronary vasomotion through stimulation of adrenergic 
receptors (93). Both α- and β-adrenergic receptors are involved in coronary vasomotion in 
response to activation of the SNS (88). Whilst β-receptors induce vasodilation, activation of the 
α-receptors concurrently induces vasoconstriction (Figure 4). In summary, differences in 
adrenoreceptor subtypes are present, which ultimately contribute to a delicate balance between 
α-mediated vasoconstriction and β-mediated dilation.  
 
Figure 4) Balance in adrenergic receptors on the endothelium and vascular smooth muscle cells 
of central arteries. Yellow boxes are endothelium-bound whereas green boxes are SMC-bound. 
Derived from (88) with permission.  
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During sympathetic stimulation, healthy endothelium mediates vasodilation through the dilator 
effects of the endothelium-bound β1-, β2-, β3- and α2-receptors (green boxes), but also through 
the β1- and β2-receptors on the SMCs (yellow boxes). These dilator effects oppose the constrictor 
effects of the α1- and α2-receptors on the SMCs. In progression of atherosclerosis, loss of 
endothelium-bound adrenoreceptors contribute to a truncated dilator response and eventually 
paradoxical constriction (14, 87). Below, these individual receptors are discussed in relation to 
the regulation of coronary artery vascular tone during sympathetic stimulation. 
α1-adrenoreceptors. On the vSMC’s, α1-adrenoreceptors have been identified, which are typically 
activated through local noradrenaline release from the adrenergic nerve terminals during 
sympathetic stimulation. Stimulation of α1-receptors leads to vasoconstriction of coronary 
arteries (88, 94, 95). Indeed, infusion of α1-agonists in patients with coronary stenosis 
demonstrated augmented coronary artery vasoconstriction (88, 90, 91). However, infusion of α1-
agonists in healthy individuals does not alter coronary vascular tone (96). The absence of a 
vasoconstrictor response in healthy individuals is most likely the result of simultaneous (mild) 
activation of β-receptors on the endothelium that counterbalances the α1-mediated constriction.  
α2-adrenoreceptors. In addition to stimulation of α1-receptors, stimulation of the α2-receptors on 
the vSMC’s mediate neurally-mediated constriction. However, stimulation of α2-adrenoreceptors 
located on the endothelium cause dilation through NO-release (88, 96-98). Indeed, several 
studies using selective stimulation found that α2-adrenergic agonists cause endothelium-
dependent relaxation in coronary arteries of healthy individuals (99), whilst concurrent 
stimulation of α2-receptors located on the SMCs mediate coronary artery constriction (96, 98). 
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Interestingly, intracoronary infusion of selective α2-agonists induced a paradoxical 
vasoconstriction in patients with atherosclerotic coronary arteries. This observation is likely 
explained through the loss of endothelial α2-receptors in atherosclerotic coronary arteries, which 
under physiological conditions mediate coronary artery vasodilation. Consequently, α2-agonists 
bind to the α2-receptors located on the SMCs, facilitating coronary artery vasoconstriction. 
Therefore, the overall effect of α2-receptor stimulation depends on the net result of both the 
endothelium- and SMC-located receptors and the functional integrity of the endothelium (96, 
100-102).   
β-receptors: The β-receptors are predominantly present on the coronary endothelium, causing 
vasodilation during sympathetic activation. There are 3 subtypes (β1, β2, β3), located on either 
the endothelium or the vascular SMCs (Figure 4), with the β2-receptor being the most abundantly 
present and most frequently studied. In healthy participants, infusion of a β2-receptor agonist 
(salbutamol) induces coronary vasodilation, suggesting a role for β2-receptors to lower 
resistance. Interestingly, administration of propranolol (a non-selective β-receptor agonist), 
partly inhibited the coronary artery vasodilator responses to sympathetic stimulation (89). Since 
β2-receptors are more strongly antagonized by propranolol than β1-receptors, the β1-receptor 
activation contributed to the remaining dilation in healthy individuals (87). In individuals with 
coronary artery disease, sympathetic stimulation leads to a paradoxical vasoconstriction during 
sympathetic stimulation. This vasomotor response may result from impaired β-receptor 
activation. To support this, intracoronary infusion of a β2-receptor agonist (salbutamol) resulted 
in impaired vasodilator responses in atherosclerotic coronary arteries (89). This supports a role 
for β-receptors to contribute to coronary artery vasodilator responses.  
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Taken together, this highlights the complex antagonistic relationship of both dilatory and 
constrictive stimuli mediated by a- b-adrenoreceptors on the endothelium and tuna media. This 
also highlights the complex progression from endothelial function, through to dysfunction and 
eventual atherosclerosis. It also highlights the loss of expression of adrenoreceptors which may 
result in this progressive loss-of-function phenotype. This complex relationship is summarized in 
Figure 4.  
Dissimilarities in carotid and coronary artery blood flow and circulation 
Although there are significant similarities in both the structure and function in the carotid and 
coronary arteries, there are also a number of dissimilarities. First, whilst both arteries are similar 
in structure and function, they experience different flow states. In the coronary arteries, the flow 
is predominantly diastolic and therefore relatively low pressures, whereas the carotid arteries 
experience predominantly systolic pulsatile pressure (103, 104). Second, the coronary arteries 
develop collateral vessel development and microcirculation particularly associated with 
ischemia. This alters flow patterns within the arteries. Although there is development of 
collateral micro-vessels within the carotid arteries this is less common than in the coronary 
arteries (104-106). Third, whilst both the carotid and coronary arteries are equally affected by 
the endocrine effects of adipokines, the coronary arteries are surrounded by perivascular adipose 
tissues. This has been demonstrated to have profound endocrine effects on vascular diameter, 
endothelial function and cardiovascular risk adiponectin as a link between type 2 diabetes and 
vascular NADPH oxidase activity in the human arterial wall: the regulatory role of perivascular 
adipose tissue(104, 107, 108).  
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2.5. Coronary Artery Endothelial Function 
The importance of coronary artery endothelial function has been demonstrated previously. 
Schachinger et al (2000) first demonstrated the importance of coronary artery endothelial 
function demonstrating that coronary artery endothelial function predicts future CVD in 
asymptomatic individuals at an increased risk of CVD (42). They investigated coronary artery 
reactivity to AChand the cold pressor test in 147 patients at an increased risk of CVD. They found 
patients who suffered cardiovascular events during follow-up had a significantly increased 
vasoconstrictor response to ACh(p=0.009) and the CPT (p=0.002). Similarly, Rubenfire et al (2000) 
investigated carotid artery response in 93 participants at average or increased risk of CVD. They 
used the cold pressor test to investigate carotid artery diameter change using carotid artery 
ultrasound. They found participants at moderate risk demonstrate carotid artery dilation in 
response to CPT. An attenuated dilator response in those at an increased risk of CVD and 
paradoxical vasoconstriction in those with coronary artery disease (14). This was a key finding in 
investigating carotid artery endothelial function. They termed the change in carotid artery 
diameter the “Carotid Artery Reactivity”. 
Carotid artery reactivity (CAR%) 
Until recently, ultrasound was typically used to examine static (i.e. IMT) or dynamic (i.e. 
compliance) characteristics of the carotid artery rather than functional responses to vasoactive 
stimuli. Based on the earlier description of marked, but similar responses of both the carotid and 
coronary arteries to sympathetic stimulation. Carotid Artery Reactivity (CAR%) was introduced as 
an alternative non-invasive method to investigate coronary artery endothelial function (42, 109). 
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The CAR% refers to the assessment of the carotid artery diameter in response to stimulation of 
the SNS, using the cold pressor test (CPT). This test involves submersion of a limb in water at a 
predesignated (typically low) temperature designed to cause a SNS response. The CPT causes 
stimulation of the SNS, leading to release of norepinephrine and dopamine that contributes to 
peripheral vasoconstriction, dilation of the carotid and coronary artery and an increase in heart 
rate (110). It has been demonstrated previously that the CPT in the carotid artery mirrors that of 
the response in the coronary artery and, therefore that the carotid artery may be used as a 
surrogate measure of coronary artery responses in healthy individuals (111). The CAR% may be 
relevant in CAD patients as well as those with increased risk such of CVD as those with CVD risk 
factors or advanced age. Previous work found that CAD patients demonstrate paradoxical 
constriction of the coronary and carotid arteries in response to CPT (109).  
In addition to the link between CAR% and coronary artery vascular function, recently work has 
explored the mechanisms underlying responses in the carotid and coronary arteries. The majority 
of the literature examining the role of adrenoreceptors in mediating central artery responses was 
performed in coronary arteries. Recently, Van Mil and colleagues examined common carotid 
(duplex ultrasound) and left anterior descending (LAD) coronary artery (Doppler ultrasound) 
responses to sympathetic stimulation (using the cold pressor test and lower body negative 
pressure respectively).  These were investigated both with and without α1-receptor blockade 
(112). They found carotid and coronary artery dilation during the cold pressor test, with α1-
receptor blockade, lead to an attenuated dilator response in both arteries. In contrast, carotid 
and coronary arteries showed constriction to lower body negative pressure was not affected by 
α1-receptor blockade. Although further work is required, this indicates similarities between 
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carotid and coronary responses to sympathetic tests (with the direction of these responses being 
dependent on the type of sympathetic stimulation), as well as in the involvement of α1-receptors 
mediation in the responses. In addition, the same researchers demonstrated moderate/strong 
correlation between the carotid and coronary responses to the CPT (113). This suggests that the 
CAR% may be used as a surrogate for coronary artery function. Taken together, this suggests 
CAR% may have a benefit in clinical risk calculators to predict risk of cardiovascular events in 
patients with pre-existing CAD. As well as in patients at increased risk with no evidence of 
previous CAD.  
Recently, Van Mil et al. (2018) found that peripheral arterial disease (PAD) patients who 
demonstrate carotid artery constriction during the CPT have an increased risk at 1 year of 
developing cardiovascular events (4.1 times), clinical deterioration (2.0 times) and other adverse 
events (AEs) (1.8 times) (114). The likelihood of this may also increase with age.  This highlights 
the potential of the CAR% in risk prediction in subjects with increased CAD risk.  
Taken together, the literature has shown that both invasive and non-invasive measures of 
endothelial function have been demonstrated to predict risk in a variety of cardiovascular disease 
groups. Van mil et al (2018) have demonstrated a correlation between carotid and coronary 
artery endothelial function (112). They have further demonstrated that carotid artery reactivity 
predicts risk in peripheral arterial disease patients (54). This thesis aims first, to better 
understand the mechanisms regulating CAR% and second, to apply the CAR% test to central 
arterial disease patient, undergoing CABG surgery to investigate if this predicts risk of AEs in 
central arterial disease patients. 
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3. Chapter 3: Thesis Goals and Objectives 
3.1. Thesis aims 
The central aim of this thesis was to investigate CAR% as a method to investigate endothelial 
function as a surrogate of vascular health  This thesis can be divided into two distinct but inter-
related studies: First, a study which explored the mechanism’s driving CAR% and second, a clinical 
study which investigated if CAR% can predict AEs and survival in patients undergoing isolated 
CABG or CABG combined with Valve Surgery.  




4. Chapter 4: Methods 
4.1. Chapter introduction 
This chapter describes the methodology employed in undertaking this research. This includes the 
ethical application process, SNS provocation using the CPT, diameter measurement and 
subsequent statistical analysis undertaken. This also highlights if the methodology is utilized in 
an individual study or both studies.  
4.2. Ethical Application 
Gaining Ethical Approval   
Study one 
Ethical approval was gained from University Research Ethics Committee (17/SPS/038).  
Study two 
Ethical approval for study one was obtained through the National Health Service (NHS) Ethics 
process (17/NW/0347). This was reviewed by the North West Coast Clinical Research Network 
and approved on 28/06/2017. No amendments were required.  
4.3. Participant Preparation 
In preparation for both study 1 and study 2, participants were asked to abstain from smoking for 
at least 6 hours, from vigorous exercise for at least 24 hours prior to testing and to avoid dietary 
products that can influence endothelial function, such as caffeine, alcohol, chocolate, and vitamin 
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C for at least 18 hours (43, 115). Testing was undertaken in a light- and temperature- controlled 
room. In either a research laboratory (study one) or clinical environment (study two).  
4.4. Participant Measurements  
Beat-To-Beat Blood Pressure Measurement 
In study one, the beat-to-beat blood pressure was measured non-invasively using 
photoplethysmography (Portapres, Finapress Medical Systems. Amsterdam, Netherlands). An 
appropriately sized finger cuff was attached to the second phalanx of the right index or middle 
finger, the transducer was placed on the wrist and a blood pressure cuff was placed on the upper 
arm. This is demonstrated in figure 5. The finometer was calibrated to the height of the 
participants heart and was allowed to auto-calibrate for two minutes as per Finapress guidelines 
(116). Before recording began, the auto-calibration was turned off as this can produce artifacts. 
The finometer was used to measure relative change in blood pressure throughout the cold 
pressor test. The reliability and reproducibility of the Finometer Pro has previously been 
investigated. It has been demonstrated to have excellent reliability and reproducibility as a 
measure of beat-to-beat blood pressure both at rest and throughout SNS stimulation. This has 
been demonstrated in both healthy and clinical groups (117-119). This made the Finometer Pro 
a valuable technique for measuring BP in this study.  
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Figure 5) A diagram of correct use and placement of the arm and finger cuff when using 
Finometer Pro. Derived from (116) with permission.  
Blood Pressure Measurement 
In study one, the blood pressure was measured with an automated sphygmomanometer (120) 
on the left arm whilst the participant was laying supine. This was measured twice with a 5-minute 
break in between. This measure was used to determine the resting blood pressure (BP) and to 
calibrate the beat-to-beat blood pressure values. Automated Sphygmomanometer has been 
previously and extensively validated for accurate measurement of resting BP (121)  
Cold pressor test 
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In both study one and study two, the CPT was used as an SNS stimulus. During the CPT, the left 
hand was immersed in a bucket of cold water (~4°C). The water temperature was measured with 
a digital thermometer (Quartz digi-thermo, Fischer scientific, Loughborough, UK) and controlled 
by adding crushed ice to maintain a stable water temperature. The participants were asked to 
position themselves close to the left edge of the bed, to ensure the hand could easily move into 
the water without significant movement of the neck. This enabled assessment of the carotid 
artery. After a 1-minute baseline period, participants were instructed to place their hand in the 
ice water for a predesignated time period. This is specified within the methods section of each 
study. The CPT has previously been demonstrated to have good same-day and next-day reliability 
and reproducibility (115, 122). The CPT has also been demonstrated to be safe in a variety of 
healthy and clinical populations (14). The arterial response in both healthy participants and in 
those at risk of CVD has been shown to be similar in response to acetylcholine (gold standard) 
and the CPT (109). The CPT was therefore used as a reliable, reproducible and safe technique 
used to stimulate the SNS. Participants were instructed not to speak, and to breathe normally in 
order to prevent hyperventilation. Hyperventilation has been demonstrated to alter carotid 
artery diameter (54, 115, 123). 
Carotid Artery Diameter Analysis 
The left common carotid artery (CCA) diameter was assessed using ultrasound sonography (L9-3 
MHz linear array probe attached to a high-resolution ultrasound machine (Terason 3300, Terason 
Labs, Burlington, Massachusetts, USA)). A longitudinal view of the artery was first used to identify 
the carotid bulb. This was identified as an anatomical landmark to standardise approximate 
 60 
scanning area between individuals. A segment of approximately 2 cms from the bifurcation was 
used to avoid turbulent flow. The common carotid artery, proximal from the carotid bulb, was 
identified and image was optimised using time gain compensation and tissue depth settings. This 
was used to ensure vessel walls are clearly defined with maximum contrast between vessel walls 
and surrounding tissue (Figure 6). Doppler velocity assessments were also recorded at the lowest 
possible angle of insonation (always <60°). The carotid artery diameter was calculated with edge 
detection software (124). On-screen calibration points were selected with the calibration tool. 
This is used to calibrate pixel-to-centimetre ratio. Calibration points were used for the diameter 
and the pulse wave velocity. A rectangle containing the largest straight artery segment was 
selected as the Region of Interest (ROI), ensuring that the vessel walls were in focus.  
 
The wall-tracking software marked the vessel walls within the ROI. The ROI used is approximately 
one third the length of the entire segment analysed. The number of pixels in each vertical column 
between vessel walls are calculated automatically. This was then used to calculate the lumen 
diameter in centimetres. This has been used previously and has been demonstrated to be reliably 
and independent of user influence (49, 111). All analysis was performed blinded and separately 
by two independent researchers (125). The sensitivity and specificity of carotid artery ultrasound 
in both research and clinical medicine has been extensively researched and demonstrated 
previously (115). Carotid Artery Ultrasound remains an accurate, reliable and reproducible non-
invasive method to investigate both static and dynamic carotid artery diameter (126-129) 
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Figure 6) A panel demonstrating Carotid Artery Response (CAR) measurement. A) A schematic 
representation of carotid artery response setup demonstrating imaging of the carotid artery 
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whilst the participants hand is in icy-cold water at 4°C. B) An image of a participants carotid artery 
demonstrating the wall tracking software and pulse-wave measurement including 
standardization tools for 1: standardization for diameter measurement and 2: standardization 
for pulse-wave velocity calculation and C) Demonstrates the carotid artery response to the cold 
pressor test including 1: Baseline diameter recording and 2: Whilst the hand is submersed in icy-
cold water.  Adapted from (54, 130) 
 
Carotid Artery Response (CAR%) 
The CAR% is the relative change in carotid artery diameter above or below baseline expressed as 
a percentage. The average diameter during the 1-minute baseline measurement was calculated 
and used as the baseline value. Subsequently, the diameter of the carotid artery was measured 
during the CPT and averaged over 10 second periods. The average, maximum and minimum 
percentages, were calculated. If the average percentage change was an increase in diameter 
(dilation), the CAR% was expressed as the maximum percentage. Conversely, if the average 
percentage change was a decrease in diameter (constriction), the CAR% was expressed as the 
minimum percentage. This is in-line with previously published work (54, 115, 123).  
Continuous BP Image Processing and Statistical Analysis 
Continuous BP analysis was undertaken for study 1. However, this could not be replicated for 
study two, as the equipment is not transferable to the hospital setting. This would have been 
beneficial to include in both studies as an increase in blood pressure may play a part in the 
dilatation/constriction response in response to SNS stimulation.  
The CAR% was calculated as described above. The BP of each participant was recorded 
continuously using the finometer (116). The baseline was calculated as the average of the BP 
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recordings across the 1-minute baseline measurement. The averaged BP measurement was then 
calculated for each ten second period. This was then correlated with carotid artery diameter to 
investigate if BP was correlated with CAR%. The mean BP was also correlated with CAR% to 
investigate the association of BP (dependent upon peripheral atrial endothelial function) and 
CAR% (central arterial endothelial function).  
Considerations in vascular ultrasound 
Carotid artery ultrasound is used commonly in clinical practice and has been demonstrated to 
have excellent same-day and next-day reliability (115). However, there are still considerations 
associated with the use and interpretation of ultrasound.  
First, although ultrasound has been demonstrated to have excellent reproducibility, this is highly 
practitioner dependent in both scan acquisition and in analysis. All participants in both of these 
studies were scanned on one occasion and therefore the reproducibility and reliability could not 
be investigated. In future studies and in clinical practice it is key to demonstrate that individual 
researchers and practitioners are suitably competent. This was unfeasible in this study.  
Second, whilst it has been shown to be reliable and reproducible, ultrasound is highly dependent 
upon proper technique and standardised protocols. The area proximal to the carotid bifurcation 
experiences turbulent flow and this may affect vasomotion and therefore CAR%. A segment 2-
3cm from the carotid bulb was therefore used to avoid this affecting recording. This was 
standardised throughout all participants. Similarly, researchers have to select an appropriate 
Region of interest (ROI) to use as a representative sample of the entire vessel. If a ROI is used 
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that is too small it may not be representative of the entire vessel. A ROI was therefore always 
used which is approximately one third of the entire length of segment scanned.  
Taken together, although vascular ultrasound is a commonly utilized, accurate and reliable 
technique. It is highly user-dependent. In future studies, researchers should demonstrate 
competency before undertaking large-scale clinical trials.  
Calculating QRISK3 score 
The QRisk3 score is a score of the probability of developing CVD in individuals with no history of 
CVD (131). The QRISK score was calculated using participant demographic data (age, weight and 
smoking status) as well as medical history. This was then used to calculate QRISK using an online 
calculator.  
4.5. Risks and Considerations during this study 
There were a number of risks and potential implications associated with both of these studies. 
First, previous studies have suggested that the cold pressor test may cause angina chest pain in 
some patients (132, 133). This chest pain was relieved by removing the hand from the water (132, 
133). Participants were therefore instructed to remove the hand from the water if they feel any 
discomfort. In study one, this research was undertaken in a busy research lab with first aid-
trained staff available. The risk of chest pain associated with the CPT was higher in patients with 
established cardiovascular disease. In study 2, these participants therefore underwent testing in 
a clinical environment. A number of the techniques employed in this PhD are also used clinically. 
There was a risk of identifying potentially clinically significant incidental findings. If any incidental 
 65 
findings were identified, the participant were referred to a relevant clinician – either their GP 
(study one) or consultant physician (study two).  
4.6. Data Analysis and Measurements 
All data is first examined for the “level” of data. The kurtosis and skewness was measured using 
a D’ Agostino-Pearson goodness-of-fit test. If there were two variables and the data was 
normality distributed, a t test was used. If the data was non-normally distributed, the non-
parametric equivalent was used. If there were more than two variables, a one-way ANOVA was 
used. If the data was non-normally distributed, the non-parametric equivalent was used. If the 
data was binary, a Chi-squared and Fischers exact test were used (95% confidence interval). 
Whereas the Chi-squared test assumes a large dataset and therefore provides an approximation, 
the fischers exact test provides an exact value and is therefore more powerful in datasets with 
less than five counts (134). If the data was continuous, normality testing was first performed 
using D’ Agostino-Pearson goodness-of-fit testing. A Pearson correlation was used is the data was 
normally distributed. If it was non-normally distributed, a Spearman correlation was used. 
Statistical significance is defined as a P<0.05. The study-specific statistical methodology is 




5. Chapter 5: Study One - A Mechanistic Study of CAR% 
5.1. Chapter introduction:  
This chapter describes a pilot study investigating the relationship between blood pressure and 
CAR%. This study aims to investigate the degree to which blood pressure response drives CAR%.  
5.2. Research question:  
Is resting blood pressure related to the magnitude of carotid artery responsiveness and blood 
pressure changes during the CAR% in middle-aged healthy volunteers? 
5.3. Aim: 
To investigate the relationship between resting blood pressure (a marker of peripheral arterial 
endothelial dysfunction) and carotid artery diameter and blood pressure responses during CAR% 
test. 
5.4. Objectives 
1. Does endothelial function relate to increase in blood pressure in middle-aged healthy 
men? 
To investigate whether CAR% relates to the blood pressure increase during the CAR-test 
in middle-aged healthy men. 
5.5. Hypothesis 
H1 The increase in blood pressure during the CAR% is related to baseline blood pressure 




Carotid artery diameter responses to sympathetic stimulation measured using carotid artery 
reactivity (CAR%) represents a novel test of vascular health and relates to cardiovascular disease 
risk. However, the regulation of CAR% is incompletely understood. This study aimed to 
investigate the relationship between the increase in blood pressure and carotid artery diameter 
response during the CAR-test in healthy, middle-aged men. The study sample consisted of 40 
normotensive men (aged 31-59) with no history of cardiovascular disease or currently taking 
medication. Non-invasive ultrasound was used to measure carotid artery diameter during the 
cold pressor test (CPT). The CAR% being calculated as the relative change in carotid artery 
diameter from baseline and expressed as a percentage. Mean arterial pressure (MAP) was 
measured with beat-to-beat blood pressure recording. The average CAR% was 4.4±5.4%, peaking 
at 92±43s. MAP increased from 88±9 mmHg to 110±15 mmHg, peaking at 112±38 seconds. Peak 
MAP was significantly later than the diameter peak (P=0.04). The correlation between resting 
MAP and CAR% was weak (r=0.209 P=0.197). Tertiles based on resting MAP or MAP-increase 
revealed no significant differences between groups in subject characteristics including age, BMI 
or CAR% (all P>0.05). Subgroup analysis of individuals with carotid constriction (n=6) versus 
dilation (n=34), revealed no significant difference in resting MAP or increase in MAP (P=0.209 
and 0.272, respectively). Taken together, the data presented in this study suggested that the 




The vascular endothelium plays an important role in regulating vascular tone, thereby 
contributing to the health and integrity of the vasculature. Several studies have revealed the 
importance of a healthy endothelium in the prevention of the progression of atherosclerosis and 
development of cardiovascular disease (15). Endothelial function has been demonstrated to 
predict cardiovascular disease in asymptomatic individuals, disease progression in patients with 
established cardiovascular disease as well as AEs and survival in patients with established CAD 
undergoing treatment (38-41).  
It has been previously demonstrated that participants with established cardiovascular disease 
demonstrate paradoxical constriction in response to SNS stimulation (109). Vasoconstriction in 
central vessels in response to SNS stimulus has been demonstrated to predict a higher risk of the 
development of CVD in asymptomatic individuals (135, 136) and disease progression and survival 
in patients undergoing treatment for CVD (14, 42, 137). A variety of techniques investigated 
vasomotion as surrogates of endothelial function. The regulation of vascular tone is achieved 
through a complex inter-connected system. This was discussed in brief below but discussed in 
greater detail in the “Background” chapter of this thesis.  
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Mechanisms of vascular tone regulation and shear stress 
Vasomotion is not the result of endothelial function alone but is a response regulated by a 
complex system which matches perfusion with requirement. This was reviewed in the 
“Background” chapter of this thesis. This is particularly important when investigating vasomotion 
in the context of provocative tests including the cold pressor test. If endothelial function, 
measured through vasomotion is to be used clinically, It was key to try to delineate the degree 
to which endothelial function regulates vasomotion. Although the CAR% method investigates 
vasomotion in the carotid artery, due to the inability to properly isolate the carotid artery, the 
coronary arteries are more commonly used within the literature. The direct measurement of 
coronary artery endothelial function requires invasive measurement and is therefore costly and 
outside of the remit of this PhD. Although this has been discussed more thoroughly in the 
“background” chapter, this was discussed in brief below. The regulation of vascular tone is 
predominantly achieved through 3 mechanisms.  
Metabolic regulation of vascular tone 
The majority of research investigating the regulation of vascular tone through metabolic demand 
has been investigated within the coronary arteries. Therefore, the research discussed below was 
predominantly conducted in the coronary arteries. It has been demonstrated previously that 
change in metabolic demand within the myocardium produce profound changes in myocardial 
perfusion. This in-turn results in change in coronary artery vascular tone. 
Krivokapich et al (1989) investigated myocardial perfusion using 13N ammonia myocardial 
imaging with Positron Emission Tomography in healthy participants at rest and throughout a 
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supine bicycle exercise test. They demonstrated that a 2.8-fold elevation in myocardial work 
(demand) was matched by a 2.2-fold increase in myocardial perfusion. Similarly, and importantly, 
the same group investigated myocardial demand and perfusion in both healthy volunteers and 
those with established coronary artery disease, demonstrated through angiography. They found 
healthy participants demonstrated a significant increase in perfusion throughout the supine bike 
exercise.  Whereas patients with significant coronary artery disease demonstrated a myocardial 
requirement-to-perfusion mismatch (138). Taken together this demonstrated first, that 
metabolic demand was a key stimulus resulting in significant increases in myocardial perfusion 
through increase in perfusion and second, that flow-limiting coronary artery disease hampers the 
ability to increase myocardial perfusion. This was thought to be caused by changes in coronary 
artery diameter as a result of CAD. Although this was not measured by Krivokapich et al (1989).  
Neurally-Mediated vascular tone 
The SNS plays a key role in maintaining and regulating vascular tone in both peripheral and 
central arteries. The vascular tone is the degree to which vasoconstrictive and vasodilatory 
stimuli affect diameter thereby allowing an increase or decrease in diameter of the vessel in 
response to physiological stimuli (14). This is largely thought to be regulated through α- and β-
adrenergic receptors on the endothelium and tunica media (87). It has been demonstrated 
previously that SNS stimulation leads to marked vasodilation within the central arteries including 
the coronary arteries (42). However in the context of progressive loss of endothelial function, 
through endothelial dysfunction and eventual atherosclerosis, it is thought that there is an 
alteration in endothelial- and SMC-bound α- and β-adrenoreceptor expression (87). In health 
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there is a balance between the pro-dilatory effects of the endothelium-bound β1, β2-, and β3- 
and α2- adrenoreceptors and the SMC-bound β1- and β2-adrenoreceptors acting in opposition 
to the pro-constrictive effects of SMC bound α1- and α2- adrenoreceptors (88). This is 
summarized in Figure 4 in the “Background” section of this thesis. It is thought that, with the 
development of endothelial dysfunction and eventual atherosclerosis, there is a loss of 
expression of pro-dilatory adrenoreceptors resulting firstly in a truncated dilatation and 
eventually in a constriction in response to an SNS stimulus (14). Mohrman et al (2013) 
investigated coronary oxygen uptake alongside α-adrenoreceptor blockade in the left anterior 
descending artery of healthy participants throughout the cold pressor test (86, 139). They found 
reduced oxygen uptake with α-adrenoreceptor blockade. This highlights the importance of 
neurally-mediated vasomotion.  
In healthy individuals, there is a net dilatory effect on both the coronary and carotid artery 
circulation in response to an SNS stimulus. Whereas in patients with coronary artery disease, 
sympathetic stimulation leads to a paradoxical vasoconstriction during sympathetic stimulation 
(42, 65). This may be as a result of impaired β-adrenoreceptor activation. In support of this, the 
β-adrenoreceptor agonist Salbutamol produces impaired vasodilator response in patients with 
established atherosclerotic coronary artery disease (14). Recently, Van Mil et al (2018) 
investigated carotid and coronary artery responses to sympathetic stimuli alongside α1-
adrenoreceptor blockade. They found attenuated carotid and coronary artery dilation in 
response to the cold pressor test alongside α1-adrenoreceptor blockade. In contrast to this, the 
coronary and carotid arteries constrict in response to lower body negative pressure both with 
and without α1-adrenoreceptor blockade. Lower body negative pressure is a chamber at the level 
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of the iliac crest whereby pressure is reduced in -10mmHg increments until it reaches -80 mmHg 
or until pre-syncope. This is used as an SNS stimulus. Taken together, this demonstrates first that 
the carotid and coronary arteries demonstrate similarities in responses to sympathetic 
stimulation and second that α1-adrenoreceptors are key in mediating this response.  
The extent to which individual mechanisms regulate vascular tone is key to investigating 
vasomotion as a surrogate of endothelial function. Vasomotion was investigated in denervated 
and regional re-innervated coronary artery segments of patients who had undergone cardiac 
transplantation (14, 88). It was found that coronary flow response to sympathetic stimulation is 
greater in re-innervated segments when compared to denervated segments (14, 88). This may 
suggest that the increase in coronary flow response to sympathetic stimulation is achieved to a 
larger extent through neurally-mediated rather than metabolic-mediated mechanisms. Although 
investigating the interaction between the metabolic and adrenergic components is very 
challenging and therefore, this is not completely understood.  
Shear Stress -Mediated vascular tone 
Endothelial function has a key role in vascular tone. However, shear stress (SS) has been 
demonstrated to have a profound role in regulating vascular tone. SS is the force that blood has 
on the endothelium as it passes through the vasculature. This friction force is opposed by tension 
and deformation in the endothelium, whilst the circumferential distension of blood pressure is 
opposed by circumferential stress (stretch) in the vessel wall (14). SS has been demonstrated to 
have a profound endothelium-dependent dilatory effect on arteries in both a dog ileac artery 
model  and in human arteries including the carotid and brachial arteries (14, 140, 141). The effect 
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of SS on carotid artery diameter is particularly important in this study. This SS-mediated dilation 
is achieved through stretch mechanosensors and is dependent upon the magnitude and direction 
of flow and the activity of NADPH oxidase. The sensing of changes in shear stress is achieved 
through several pathways such as platelet endothelial cell adhesion molecule 1 (PECAM-1), 
integrins, ion channels and tyrosine kinase receptors (142). It was demonstrated that NO 
inhibition abolished SS-related dilatation demonstrating that SS-mediated dilatation was a 
function of endothelial function through NO production (91, 143). This therefore means that an 
increase in blood pressure may affect vasomotion through the SS stimulus and that the 
magnitude of blood pressure increases and therefore increase in SS may impact CAR% (91, 143). 
Vita et al (1992) investigated coronary artery SS in healthy and atherosclerotic coronary arteries 
by increasing coronary artery blood flow using infusion of intracoronary adenosine. They found 
that, in healthy coronary arteries, increase in SS results in a coronary artery vasodilation (91, 
143). This is likely through the increase in transmural pressure. Whereas in atherosclerosis, 
failure of this dilatory mechanisms results in greater change in SS which may negatively affect 
expression of anti-atherosclerotic transcription factors (144). This is achieved through an 
alteration in expression patterns of pro- and anti-atherosclerotic genes, tipping the balance 
towards pro-inflammatory and pro-atherogenic associated with turbulent flow. This flow-specific 
response is achieved through endothelial sensing of ROS (144). Similarly and importantly an 
increase in SS caused by hypercapnia results in an increase in vasodilation of the internal carotid 
artery in healthy individuals (145). Taken together, this highlights the ability of SS to affect carotid 
artery diameter.  
Shear Stress (SS) and CAR% 
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Shear stress is relevant when investigating vasomotion as a surrogate of endothelial function 
because an increase in blood pressure as seen during the CPT may affect vasomotion as a 
hemodynamic stimulus. The magnitude of blood pressure increase may reflect sympathetic drive 
(36, 146). This therefore highlights the importance of better understanding the effect of blood 
pressure (and therefore SS) on endothelial function and therefore vascular tone.  
In an attempt to better understand the effect of blood pressure (and therefore SS) on 
vasomotion. This study investigated the relationship between the timing and magnitude of a 
sympathetically induced elevation in blood pressure and carotid artery diameter responses in 
healthy, middle-aged men. This group was included because this group demonstrates a good 
diversity of blood pressure and diameter responses to the cold pressor test, whilst being less 
likely to have significant age-related negative impacts on endothelial function. The endothelially-
protective effects of estrogen are also a key confounding variable and therefore we investigated 
men only (77, 147). In future studies, sub-group analysis including pre- and post-menopausal 
women and women receiving hormone replacement therapy should be investigated. An increase 
in blood pressure is associated with a relatively large transmural pressure (i.e. hemodynamic 
stimulus relevant for vasomotion) and sympathetic stimulation (i.e. stimulus for carotid artery 
vasomotion). This increase in blood pressure will result in an increase in shear stress. It is 
hypothesised that a large blood pressure change (and therefore shear stress) will produce a 
larger dilatory stimulus and therefore a larger CAR%. This is a potential confounding variable and 
therefore this study aims to investigate the degree to which the increase in BP (and therefore SS) 





Forty healthy men aged 31-59 years old with no history of cardiovascular disease were recruited 
from Liverpool John Moores University. Exclusion criteria were: a history of cardiovascular 
disease, history of diabetes, currently using cardiac medication for cardiac arrythmias, 
hypertension or hypercholesterolemia or those who have known or suspected Raynaud’s 
syndrome or those with known or suspected carotid artery disease or endarterectomy. All of 
which were self-reported through the pre-testing questionnaire. Any participants who described 
Raynaud’s-like symptoms or who weren’t sure were also excluded. This exclusion criteria were 
selected as these are all known to affect endothelial function or blood pressure response (49, 
54). As this study was investigating the relationship between endothelial function and blood 
pressure, participants with confirmed conditions or medication which is known to affect 
vasomotion, blood pressure response or SNS activation were also excluded. This was in-line with 
current guidelines for investigating endothelial function (49)  and was in-line with previously 
published research (54).   
Procedure  
Local ethical approval from the Liverpool John Moores University was gained on 17/8/2017 
(17/NW/0347). Informed consent was obtained and formally documented for each participant. 
Participants were asked to abstain from smoking for at least 6 hours, from vigorous exercise for 
at least 24 hours prior to attending the laboratory and to avoid dietary products that can 
influence endothelial function, such as caffeine, alcohol, chocolate, and vitamin C for at least 18 
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hours. This was in line with current guidelines and previously published work (43, 115). 
Participant’s body weight and height were measured on arrival. Participants would then lay on a 
bed in a quiet, light and temperature controlled room (43, 115) and completed a non-validated 
healthcare questionnaire which included medical history, CVD related lifestyle risk factors, family 
history and current/previous medications prior to testing. The QRisk3 score was calculated for 
each participant using the online QRisk3 calculator. This is used clinically to predict risk of 
cardiovascular disease and events in patients with no history of cardiovascular disease (148) 
Physiological Measurements 
Blood pressure 
The resting blood pressure reading was measured with an automated sphygmomanometer 
(Dynamap Procare 400) in duplicate with 5 minutes in-between (120). A period of at least 5 
minutes was allowed after the BP cuff was used before the cold pressor test was performed. This 
is because inflation of the BP cuff may have an effect on the SNS and therefore alter CPT 
response. The left arm was used whilst the participant was laying supine. This measure was used 
to calibrate the beat-to-beat blood pressure values. To measure beat-by-beat blood pressure, a 
finapress finometer pro model was used. The second phalanx of the right index or middle finger 
was measured and the most appropriate finometer finger cuff selected. The finometer was 
calibrated to the height of the heart for each individual participant. The finometer was then 
allowed to auto-calibrate for two minutes as per manufacturer instructions. The correct 
participant preparations and finometer cuff place is demonstrated in Figure 5. This was in-line 
with manufacturer’s guidelines (116). The finometer has been demonstrated to be a reliable and 
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reproducible measure of beat-to-beat blood pressure monitoring during both resting (117) and 
throughout SNS stimulation using both the cold pressor test and exercise stimulus (149) .    
 
 
Figure 5) A schematic representation of appropriate arm, finger and wrist placement taken from 
Portapress Finapress manufacturer guidelines (116)  with permission.  
Cold Pressor Test 
The Cold Pressor Test has been previously demonstrated to be a reliable and reproducible 
method of stimulating the SNS in both healthy participants and in those with cardiovascular 
disease (42, 115). During the CPT, the left hand was immersed in a bucket of cold water (~4°C). 
This temperature has been previously demonstrated to be sufficient to elicit a safe and 
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reproducible SNS response whilst being well tolerated with participants (54). The water 
temperature was measured with a digital thermometer (Quartz digi-thermo, Fischer scientific, 
Loughborough, UK) and controlled by adding crushed ice to maintain a stable water temperature. 
The participants were asked to position themselves close to the left edge of the bed, to ensure 
the hand could easily move into the water without significant movement of the neck. This 
avoided artefacts or movement during recording.  
Participants were instructed not to speak, to breathe normally and to remain as still as possible 
throughout testing. As participants may hyperventilate, they were encouraged throughout. This 
avoided disturbance throughout recording. This was in-line with previously published research 
(115, 130). A one minute “baseline” period was first recorded prior to the hand being placed in 
the water. After the initial one-minute period, the participant was instructed to place the hand 
in to the water whilst remaining still. The hand was held in the water for three minutes. 
Participants were also asked not to speak, and to breathe normally throughout to avoid 
hypercapnia. The participant was verbally encouraged throughout (54, 115, 123).  
Carotid Artery Diameter Imaging 
The left common carotid artery diameter was imaged using vascular ultrasound sonography 
(Terason 3300, Terason Labs, Burlington, Massachusetts, USA). The carotid bulb of the left 
carotid artery was first imaged in a longitudinal view. The carotid bulb was identified as an 
anatomical landmark and used to standardise approximate scanning area between individuals. A 
segment proximal from the carotid bulb, was identified and the image was optimised using time-
gain compensation and depth. The image was optimised until artery walls were clearly defined 
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with maximum contrast between vessel walls and surrounding tissue. (Figure 9). On-screen 
calibration points were selected with the calibration tool.  This allowed software to calculate the 
pixel-to-centimetre ratio. The calibration points were used for the diameter and the pulse wave 
velocity. A rectangle containing the largest straight artery segment was selected as the (ROI), 
ensuring that the vessel walls were in focus. The software marked the vessel walls within the ROI 
with lines and calculated the number of pixels in each vertical column. From the pixel distance 
the software calculated the lumen diameter in centimetres. This was all in line with previously 
published research (14, 54, 115) and is discussed in further detail in the “methods” section of this 
thesis.  
Carotid Artery Response (CAR%) 
The CAR% is the relative change in carotid artery diameter above or below baseline expressed as 
a percentage. The average diameter during the one-minute period before submersion was 
calculated and used as the baseline value. Subsequently, the diameter of the carotid artery was 
measured during the CPT and averaged over ten second periods throughout both baseline and 
throughout the stimulus. The average, maximum and minimum percentages were calculated. If 
the average percentage change was an increase in diameter (dilation), the CAR% is expressed as 
the maximum percentage. Conversely, if the average percentage change was a decrease in 
diameter (constriction), the CAR% is expressed as the minimum percentage. This was in-line with 
previous work utilizing the cold pressor test. (54, 115, 123) 
Blood pressure 
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The beat-to-beat blood pressure data was processed in the same way as the CAR% calculation.  
Beat-to-beat blood pressure was measured and then MAP calculated. Baseline was the average 
MAP (AVGMAP) during the one minute prior to the hand being placed in water. The average MAP 
during the CPT was calculated for each ten second period, matching the epochs for diameter as 
described earlier. The systolic and diastolic blood pressure measured with the 
sphygmomanometer was used to calculate the MAP before testing. The beat-to-beat blood 
pressure data was calibrated using the resting blood pressure measured using an automated 
sphygmomanometer (Dynamap). The cuff was placed around the left arm and performed twice 
(with a five-minute rest period in between). A period of at least 10 minutes was given between 
this and performing the CPT. The maximum change in blood pressure was expressed as the 
maximum increase (ΔMAP) and maximum percent increase in MAP (relative ΔMAP) compared to 
baseline during the CPT. 
Statistical analysis 
All data were presented as mean ± SD. Statistical analysis was performed using IBM SPSS Statistics 
25 (IBM SPSS; IBM Corp., Armonk, New York, USA). Pearson correlations were employed to 
examine the relationship between baseline MAP and the change in blood pressure during the 
cold pressor test (ΔMAP) versus the CAR% (i.e. relative change in diameter compared to 
baseline). The relationship between the timing of the peak responses in BP versus CAR% was also 
investigated using a Pearson correlation. Participants were divided in to tertiles based on the 
relative change in BP during the CPT: low (<15%), medium (15-30%) and high (>30%). One-way 
ANOVA was used to examine difference between groups in general characteristics including age, 
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BMI and cardiovascular risk and CAR%. Tukey post-hoc analysis was performed to examine which 
groups differed from each other. Statistical significance was set at p<0.05. 
5.9. Results 
The results were divided in to six different sections. First, a description of the characteristics of 
the population. Second, a study investigating the change in both carotid artery diameter and 
blood pressure in the whole group throughout the CPT. Third, a study investigating the effect of 
age on endothelial function to investigate age as a confounding variable. Fourth, a study 
investigating the relationship between cardiovascular risk factors, MAP and carotid artery 
diameter to investigate cardiovascular risk factors as confounding variables. Fifth, the 
relationship between change is blood pressure throughout the CPT and CAR% when healthy male 
participants are grouped according to their blood pressure response to the CPT. Sixth, is 
investigating the demographics in participants grouped according to if they demonstrate a 
“dilation” or “constriction” CAR% response throughout the CPT. This was to investigate the 
impacting of confounding variables on the CAR% response in this group.  
Participant Demographic Data 
40 healthy men aged 31-59 were included.  The average age of participants was 46±12 years. 
These participants had an averaged BMI of 27±4 kh/m2. They were normotensive with a systolic 
BP of 123±12 mmHg and a diastolic BP of 74±5 mmHg. The average QRisk3 score was 4.9±4.94. 
A secondary aim of this study was to investigate endothelial function in both normotensive and 
hypertensive participants, to investigate if there is a significant difference in central arterial 
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endothelial function in normotensive and hypertensive participants. However, as all participants 
were normotensive, this was not possible.  
Table 2) Demographic data of all participants involved in the trial. Demographic data is expressed 
as mean with SD.  
  
  
Age (years) 46±12 
Weight (kg) 80.41±15.32 
Height (meters) 1.73±0.05 
BMI (kg/m2) 27±4 
Systolic BP (mmHg) 123±12 
Diastolic BP (mmHg) 74±5 
QRISK (%) 4.91±4.94 
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Diameter and Blood Pressure Response to the CPT 
This study first began by investigating both the change in both carotid artery diameter and 
brachial artery MAP throughout the CPT in all participants. This also investigated the relationship 
between timing of peak diameter and peak MAP response. The MAP is derived from beat-by-
beat blood pressure recording. The MAP gradually increased with all participants demonstrating 
a statistically significant increase in MAP throughout the CPT (figure 7). MAP gradually increases 
within 30 seconds. Peak MAP occurred at 112±38 seconds with a gradual decline at ~130 seconds. 
There was also a statistically significant increase in mean diameter through the CPT. This is 
demonstrated in figure 7. The diameter gradually increased after a period of ~10 seconds and 
peaked at 92±43 seconds. A Pearson correlation was used to investigate the correlation between 
MAP and diameter. There was no correlation between peak MAP and peak diameter timing in 
this group (R = 0.03, P = 0.30).  
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Figure 7) Mean and Standard Deviation of all-participants response during the cold pressor test 
(CPT). Both carotid artery diameter and brachial artery blood pressure plotted against time. One-
Way ANOVA performed to investigate statistical significance of change from baseline 
measurement to increase in both MAP and diameter plotted against time. * denotes P= <0.05, 
** denotes P:<0.01, *** denotes P=<0.001 ****denotes P:0.0001.  
 
 85 
Young vs old participants 
To investigate the impact of age on response participants were divided according to their age. 
“young” participants were considered as those aged 31-45 and “older” patients as 46-60. It is 
thought that the decline in endothelial function is non-linear and associated with “unhealthy” vs 
“healthy” aging and significant fall in in “middle aged” participants. The participants were 
therefore grouped in to “young” and “old” rather than a correlative relationship. here was a 
statistically significant difference in age between these two groups (P = 0.0001). There was also 
a statistically significant difference in weight (P=0.0196), BMI (P = 0.0247) and QRisk3 (P= 0.0001). 
The “older” participants had a higher height, weight, BMI and QRisk3 score (Table 3). When 
examining both MAP and diameter data at baseline and throughout the CPT, there was also a 
statistically significant difference in average diameter (P = 0.0408) and max diameter (P = 0.0313). 
When comparing “Young” vs “Old” participants (Table 4). The “older” participants had a higher 
average and maximum diameter throughout CPT.  
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Table 3) Demographic data of participants separated according to their age into young (n=26) 
and older (n=14) subjects including SD. An independent samples t test was performed. 
Significance defined as p=<0.05 







Age (years) 36±5 53±5 0.01* 
Weight (kg) 78±11 90±13 0.01* 
Height (meter) 1.76±0.07 1.78±0.06 0.49 
BMI (kg/m2) 25±3 28±4 0.02* 
Systolic BP (mmHg) 122±9 128±14 0.08 
Diastolic 
BP(mmHg) 
71±11 72±8 0.51 
QRISK (%) 1.52±1.33 6.91±2.82 0.01* 
 
Table 4) Mean Arterial Pressure and carotid artery diameter responses in participants at baseline 
and average MAP throughout the CPT in participants when separated according to “young” (30-
45, n=26) and “older” (46-60, n=14) 
 Young (n=25) Older (n=15) 





108±14 91±10 104 115±17 
Diam 
(cm) 
0.65±0.05 0.66±0.04 0.68±0.04 0.69±0.07 0.71±0.07 0.73±0.07 
 
Table 5) Statistical comparison of “old” vs “young” baseline, average and max MAP and CAR% 
throughout the CPT. “Young” defined as aged 30-45 (n= 26) and “old” defined as 46-60 (n=14). 
Unpaired t test with Welch’s correction performed. * denotes statistical significance. Statistical 
significance defined as p=<0.05  
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MAP Young vs old Diameter Young vs Old 
Measure P value Measure P Value 
Baseline 1 0.25 Baseline1 0.05 
AVG MAP 2 0.37 AVG Diameter2 0.04* 
Max MAP 3 0.19 Max Diameter3 0.03* 
Min MAP 0.65 Min Diameter 0.76 
1Baseline defined as baseline period before CPT 
2Average defined as average increase throughout the CPT 
3Max defined as the maximum increase throughout the CPT.  
AVGMAP% vs Cardiovascular Disease Risk Variables 
To investigate the relationship between MAP and CVD risk factors, linear regression analysis was 
performed. This investigated the relationship between average increase in MAP and a number of 
factors known to be associated with cardiovascular risk. The MAP expressed as an average of the 
increase in MAP above baseline and was expressed as a percentage (AVGMAP%) There was no 
correlation between AVGMAP% and any of the cardiovascular disease associated risk factors in 
this group. (Table 6) 
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Table 6) Pearson linear relationship between the average increase in MAP throughout the CPT 
when compared to baseline MAP expressed as a percentage (AVGMAP%) compared to 
cardiovascular risk factors.  
AVGMAP% vs Variable R2 Value P Value 
AVGMAP% vs Systolic BP 0.01 0.63 
AVGMAP% vs BMI 0.02 0.81 
AVGMAP% vs CAR% 0.08 0.08 
 









Association of Blood Pressure and Cardiovascular Risk 
“High” vs “Low” Blood Pressure and Cardiovascular Risk Factors 
To investigate the relationship between change in MAP throughout the CPT. The participants 
were divided according to the relative increase in blood pressure in response to the CPT. In this 
study, “Low relative” BP response was defined as <15% increase (n=8), “Medium relative” BP 
response defined as a 15% and 30% change (n=20) and a “high relative” response defined as 
greater than 30% (n=12). All responses were percentage increase in (MAP) above baseline MAP 
throughout the CPT.  There was a statistically significant difference in baseline MAP (P = 0.053), 
Peak MAP (P = <0.001) and Relative ΔMAP (P = <0.001) in the low relative, medium relative and 
high relative ΔBP groups.    
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Table 7) CAR% and blood pressure results of the groups divided based on relative ΔMAP (low= 
<15%, medium = between 15% and 30%, high = >30%). Relative ΔMAP was defined as the percent 
increase from baseline to the peak MAP. Unpaired T Test performed. A) Post-hoc significantly 












Age (years) 42.61 ± 9.31 40.92 ± 9.21 44.33 ± 10.61 0.61 
Weight (kg) 83.51 ± 12.32 81.21 ± 11.73 83.92 ± 15.32 0.82 
Height (meter) 1.76 ± 0.08 1.77 ± 0.07 1.79 ± 0.07 0.60 
BMI (kg/m2) 26.71 ± 2.21 26.01 ± 3.54 26.12 ± 4.65 0.89 
Positive family history (yes) 1.51± 0.76 1.23 ± 0.83 1.34 ± 0.81 0.66 
Baseline diameter (cm) 0.67 ± 0.05 0.65 ± 0.05 0.69 ± 0.08 0.22 
CAR (%) 1.33 ± 4.63 4.51 ± 4.51 6.42 ± 6.53 0.11 
Baseline MAP (mmHg) 95 ± 11 85 ± 8 90 ± 9 0.05* 
Peak MAP (mmHg) 102 ± 13 106 ± 10 125 ± 15ab <0.01
* 
Relative ΔMAP (%) 7.54 ± 4.32 23.71 ± 3.92a 38.01 ± 4.00ab <0.01
* 
 
Table 8) Mean plus/minus SD MAP and Diameter data of participants when split into groups 
according to their ΔMAP (low= <15%, medium = between 15% and 30%, high = >30%). Relative 




 Low relative ΔBP (n=8) Medium relative ΔBP (n=20) High relative ΔBP (n=12) 
Baseline AVGCPT MaxCPT Baseline AVGCPT MaxCPT Baseline AVGCPT MaxCPT 
MAP 
(mmHg) 
94±11 94±13 102±13 85±8 97±9 106±10 90±9 113±14 125±15 
Diam 
(cm) 
0.69±0.05 0.68±0.06 0.69±0.07 0.65±0.50 0.66±0.05 0.68±0.05 0.69±0.08 0.71±0.07 0.73±0.06 
 
Table 9) Statistical comparison investigating overall effect of MAP and Diameter during baseline, 
AvgCPT and MaxCPT in participants grouped “low”, “medium” and “high” according to their 
ΔMAP. One-way ANOVA performed.  
MAP Low, Medium, High Diameter Low, Medium, High 
Measure P Value Measure P Value 
Baseline 0.05 Baseline 0.22 
AVGCPT 0.01* AVGCPT 0.08 




Differences in Characteristics in Whole Group, “Dilator” and “Constrictors” 
The participants were then separated using their Carotid Artery Response (CAR%) to the CPT. The 
“dilator” group were defined as participants who demonstrate a positive CAR% to the CPT (N= 
34). The “constrictor” group were participants who demonstrate a negative CAR% to the CPT 
(N=6). Independent Samples T Test performed. There was no significant difference in any of the 
demographic measures in these two groups (Table 10). There was a statistically significant 
difference in CAR% in these two groups (5.7± 4.7 in “Dilators” and -2.8± 2.48 in the “Constrictor” 
group. P = <0.001) (Table 10).  
Table 10) Participant characteristics and CAR% when divided into groups based on the presence 
of diameter dilation or vasoconstriction. P-values refer to an unpaired t-test comparing Dilator 
vs Constrictor groups.  
 
 Total (n=40) Dilator (n=34) Constrictor (6) P-value 
Age (years) 42.25±9.53 42.08±9.31 43.17±12.01 0.90 
Weight (kg) 82.46±12.73 81.05±11.24 90.32±18.71 0.34 
Height (meter) 1.77±0.07 1.78±0.07 1.75±0.05 0.65 
 BMI (kg/m2) 26.16±3.63 25.58±2.91 29.37±5.32 0.06 
Number of risk factors 0.43±0.30 0.44±0.50 0.17±0.41 0.37 
Baseline diameter (cm) 066±0.06 0.67±0.05 0.66±0.10 0.43 
CAR (%) 4.42±5.42 5.71±4.73 -2.92±2.48 <0.01* 
Baseline MAP (mmHg) 84.53±22.23 88.72±7.43 91.51±82.12 0.46 
Peak MAP (mmHg) 111±15 110±15 109±19 0.29 
Relative ΔMAP (%) 14.12±14.21 22.01±10.43 20.23±15.21 0.518 
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Table 11) Correlation between CAR% and the blood pressure variables during CPT for all 
participants, constrictor and the dilation group. ΔBP is the absolute difference between peak and 
baseline blood pressue, whereas relative ΔBP is the percent increase from baseline to the peak 
blood pressure. Pearson correlation.  











-0.35 0.03 -0.59 <0.01* 0.16 0.76 
Baseline MAP  0.21 0.20 0.30 0.09 0.22 0.67 
Peak MAP  0.36 0.02* 0.42 0.01* 0.46 0.36 
ΔMAP 0.33 0.04* 0.33 0.06 0.43 0.39 
Relative ΔBP 0.27 0.09 0.23 0.20 0.65 0.16 






The primary aim of this study was to investigate the relationship between changes in blood 
pressure and carotid artery diameter during the CPT. This study presented the following key 
findings. First, the start of dilation and the timing of the peak carotid artery diameter response 
preceded blood pressure changes during the cold pressor test. Second, there were no differences 
in baseline characteristics including age, weight, BMI or in the magnitude of carotid artery 
dilation when comparing groups based on the magnitude of blood pressure increase. This finding 
was supported by the lack of correlation between the relative changes in carotid artery diameter 
and blood pressure during the CPT. Finally, individuals who demonstrated carotid artery 
vasoconstriction demonstrated a comparable increase in blood pressure to those who dilate 
during sympathetic stimulation. Taken together, this study suggested that the characteristic 
increase in blood pressure during sympathetic stimulation did not significantly contribute to 
carotid artery vasomotion in healthy men aged 31-59. However, it should be acknowledged that 
there was no significant difference in risk factors or BMI when groups were separated in to 
“dilator” vs “constrictor” groups or when participants were grouped according to their blood 
pressure response. There was also no significant difference in QRIsk3 score (A score used 
clinically to predict CVD risk in asymptomatic individuals) in the “dilator” vs “constrictor” group 
(p=0.4096) (Data not shown). It also should be noted that confounding variables not measured 
such as exercise and diet may also have an impact on the lack of correlation between BP and 
CAR% (150)  
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The CPT is a frequently used procedure to activate the SNS in humans. As expected, and in line 
with several previous studies, blood pressure gradually increased after a period of 20-30 seconds. 
The increase in blood pressure was most likely the result of (nor)adrenaline release, mediating a 
vasoconstriction response in peripheral arteries that cause an increase in total peripheral 
resistance (151, 152). Interestingly, the timing of the start of carotid artery dilation, and the 
timing of the peak diameter change, significantly preceded the blood pressure response. This 
suggested that contrary to our hypothesis, carotid artery response was not directly linked or 
driven by the increase in blood pressure response during the cold pressor test. To further support 
this conclusion, there was no relation between the degree of blood pressure increase and the 
CAR% during the CPT. A final strong argument against a key role for blood pressure in mediating 
the carotid artery vasomotor response during the cold pressor test was the presence of 
vasoconstriction in some individuals. A significant increase in blood pressure was found in these 
individuals, which did not differ from the blood pressure response found in subjects with carotid 
artery dilation.  This study involved healthy participants with no previous history of 
cardiovascular disease. However, it should be noted that the average BMI of these participants 
is 27±4. This means that on average, the participants were overweight. This may have an impact 
on endothelial function and therefore may be a confounding variable.  
Despite the absence of a relation between the diameter and blood pressure response, both 
responses seemed strongly related to sympathetic stimulation. Indeed, catecholamine-release 
during sympathetic stimulation seem directly related to carotid artery responses (153). This 
catecholamine release may also be responsible for the increased peripheral artery resistance and 
blood pressure changes (153). Differences in sensitivity of receptors or mechanisms contributing 
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to vasomotion between central (i.e. carotid) and peripheral arteries may explain the difference 
in timing of the blood pressure and diameter responses. Nonetheless, given their dependence 
on catecholamines (154), it was expected a relationship between the magnitude of blood 
pressure and diameter response would be identified. One potential explanation for the lack of 
relation is that catecholamine-release was less strongly related to vascular responses than 
anticipated. Cummings et al. (1983) found adrenalectomised participants do not demonstrate an 
increase in adrenaline, noradrenaline or dopamine during the CPT, despite the presence of an 
increase in blood pressure of comparable magnitude to healthy individuals. Therefore, peripheral 
artery responses (and therefore blood pressure) to the CPT may be independent of 
catecholamine release (155), whilst catecholamines seem essential for carotid artery diameter 
responses. At least, this study suggested no direct link between blood pressure and carotid artery 
diameter response to the CPT in healthy individuals.  
An important factor to consider is that structural properties of the artery may influence the 
dilator response. A previous study demonstrated a negative correlation between baseline carotid 
diameter and CAR% in non-diseased average risk, high risk, and coronary artery disease patients, 
but not with the carotid artery intima-media wall thickness (IMT) (109). In contrast, Van Mil et al. 
reported no correlation between the baseline carotid diameter or IMT and CAR% in healthy 
people (115), whilst others also found no correlation between coronary artery baseline diameter 
and dilation response (143). In this study, there was a significant, but weak, inverse correlation 
between the baseline carotid diameter and the CAR% in the whole group, implying that a smaller 
baseline diameter correlates with a larger CAR%. This observation fits with several previous 
studies examining peripheral arteries, where a smaller brachial or femoral artery correlates to a 
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larger flow-mediated dilation (156, 157). The presence of a correlation between diameter and 
CAR% in this study, whilst largely absent in previous work, may relate to the inclusion of healthy 
individuals only. For example, previous work in peripheral arteries also found a weaker or non-
existing correlation between baseline diameter and dilator responses in older and diseased 
populations (158). This may be explained by the impact of older age and/or cardiovascular risk 
factors in those groups. This may affect both baseline diameter and dilator response. 
Consequently, affecting the (weak) inverse relation between both parameters in healthy young 
individuals. At least, this study suggests that structural characteristics of the artery wall should 
be considered when examining the CAR% responses, but unlikely affect or interfere with the 
blood pressure increase (and subsequent diameter response) during the CPT. Due to scan quality, 
structural analysis such as IMT was not possible.  
Limitations.  
One potential limitation in this study was that the results of our study only apply to healthy men, 
making extrapolation to other groups as well as women difficult. This is important because 
distinct populations have demonstrated different CAR% and/or blood pressure response (159, 
160), whilst also physical activity may affect the blood pressure and/or CAR% (161). Nonetheless, 
it seems unlikely that these confounding factors, despite their role in changing blood pressure 
and/or CAR%, affected the relationship between the blood pressure and diameter increase 
during the CPT. Another limitation was that our study did not explore the causal link between 
blood pressure and CAR%. To investigate this, a study would require direct manipulation of the 
blood pressure response during sympathetic stimulation. Monahan et al (2013) examined the 
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impact of the CPT on the left anterior descending artery with α- and β-adrenergic antagonists 
(139) and found adrenergic blockade to abolished coronary artery vasodilation. In agreement, 
Van Mil et al (2018) examined carotid and coronary artery responses during the CPT with and 
without α1-receptor blockade, and reported abolished carotid and coronary artery responses 
when combined with α1-receptor blockade (113). Whilst this provided evidence for the role of 
adrenergic receptors in contributing to carotid (and coronary) artery vasodilation during the cold 
pressor test, the presence of an increase in blood pressure during blockade hampered 
conclusions pertaining to the role of blood pressure per se.  
In conclusion, findings from this small pilot study suggested that carotid artery diameter changes 
during the CPT are unlikely related to the characteristic increase in blood pressure. The start and 
peak of the diameter preceded that of the blood pressure, whilst no correlation was present 
between the magnitude of the blood pressure response and CAR%. Moreover, even individuals 
who presented carotid artery vasoconstriction demonstrated an increase in blood pressure, 
making it unlikely that the blood pressure rise should be regarded as the dilator stimulus. This 
study added evidence that CAR% provides a measure of vasomotion, independent of the increase 
in blood pressure during the CPT. 
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6. Chapter 6: Correlation of Carotid Artery Response to Surgical Complexity and Outcomes in 
Patients undergoing Coronary Artery Bypass Graft Surgery 
6.1. Chapter introduction:  
This chapter describes a clinical study investigating if CAR% predicts risk in patients undergoing 
CABG surgery.   
6.2. Research question:  
Does pre-surgery assessment of the CAR% predict post-surgery outcomes (i.e. 30-day AEs) in 
patients with coronary artery disease undergoing CABG surgery? 
6.3. Aims: 
 To explore the prognostic value of carotid artery reactivity (CAR%) to predict post-surgical AEs 
in patients with CAD undergoing CABG surgery combined with valve surgery. 
6.4. Objectives: 
1) Does a reduced CAR% result in a higher incidence of AEs in patients undergoing CABG 
combined with  valve surgery? 
To explore if a reduced CAR% is associated with a higher incidence of AEs in patients 
undergoing CABG combined wtih valve surgery 
2) Does CAR% correlate with EuroSCORE II score in patients undergoing CABG combined 
with valve surgery? 
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To explore if CAR% predicts AEs more accurately than EuroSCORE II in patients 
undergoing CABG. 
6.5. Hypothesis 
H1 CAR% Predicts short term (30 day) incidence of AEs post CABG-surgery 




Coronary artery endothelial function has been demonstrated to predict risk of disease 
progression and survival in a variety of clinical groups (109). In health, there is an endothelium-
dependent dilation. Whereas, in patients with cardiovascular disease risk, this is reduced. In 
patients with severe coronary artery disease, there is a paradoxical constriction (14, 109). This is 
measured invasively using quantitative angiography. The carotid arteries may be uniquely placed 
to offer a simple imaging target with both structural and functional similarities to the coronary 
arteries (14). The carotid and coronary arteries also demonstrate a similar response to SNS 
stimulation (112). Recently, our group demonstrated that CAR% predicts risk of disease 
progression and AEs in patients with PAD (54). The aim of this study was to investigate if CAR% 
predicts risk in patients with central (coronary) artery disease undergoing coronary artery bypass 
graft surgery (CABG). A sample of 95 participants were included in analysis. Participants 
underwent provocation testing using the CPT alongside CAR%. Patients were then followed-up 
for incidence of AEs and survival for 30 days post-operatively. There was a weak inverse 
correlation between CAR% and EuroSCORE II (P: 0.01 r: -0.26). EuroSCORE II (current clinical 
practice) did not predict AEs in this group (ROCAUC: 0.60). CAR% also did not predict risk in this 
group (ROCAUC:0.51). When combined, CAR% marginally improved predictive ability 
(ROCAUC:0.615). Although this was still not predictive of events. This may have been due to the 
small number of events within our study (ten total). It may also have been that CAR% alone does 
not predict AEs but when combined with current risk prediction tools (EuroSCORE II) this 
improves the predictive capacity. This requires further work.  
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6.7. Background 
Coronary Artery Bypass Graft Surgery 
Coronary Artery Bypass Graft (CABG) Surgery is one of the most common cardiac surgical 
interventions undertaken with approximately 800,000 operations undertaken world-wide each 
year (162). CABG surgery is offered on the grounds of symptom relief and  prognostic benefits in 
patients where medical therapy or percutaneous coronary intervention (PCI) are unsuccessful or 
inappropriate (163). In CABG surgery, an artery or vein is used from elsewhere within the body 
to bypass the flow-limiting lesion in the coronary artery. This procedure restores flow to the distal 
tissue providing both symptom relief and prognostic benefit (9). The process of coronary artery 
bypass graft surgery and conduit vessel selection are discussed extensively elsewhere (9). A 
second common dysfunction within the heart is valvular regurgitation/stenosis. The cardiac 
valves are responsible for controlling blood flow around the heart and are instrumental in 
avoiding retrograde flow within the heart. However, these valves can become dysfunctional and 
allow regurgitation and subsequent heart failure. Surgical interventions to repair or replace these 
valves aim to restore function thereby restoring directional flow throughout the heart. CABG 
surgery is the most commonly undertaken cardiac surgical intervention whereas CABG combined 
with valve surgery is the most common combined cardiac surgical procedure (164). There is a 
significant body of research investigating the characteristics of CABG surgery. This is key as CABG 
is offered to a wide variety of patients with a large variability in their risk profile. It is also key 
that patient characteristics including risk profile are reported in prognostic studies to allow 
individual prognostic studies be understood in the context of the larger literature.  
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 This is in-line with the PROGnosis Research Strategy ( PROGRESS) framework for undertaking 
and reporting prognostic studies (165, 166). It is therefore key that risk prediction tools are 
understood in the context of the risk profile of individual research studies and are not over-
extrapolated. One of the largest meta-analyses investigating characteristics of patients 
undergoing CABG surgery have been used to characterize approximately 32000 patients 
undergoing CABG surgery (167).  
Risk and Risk Prediction in CABG Surgery 
Although CABG surgery is a commonly utilised treatment for CAD, it is associated with some risk. 
According to a large meta-analysis of 13327 procedures in North American, cumulative short-
term (30 day) risk of operative mortality in isolated CABG surgery is approximately 2.1% in men 
and 3.9% in women (167).  Whereas short-term (30 day) cumulative risk of AEs, are 2.4% risk of 
MI, 1.3% risk of stroke, 1.5% risk of GI bleed and 0.8% risk of renal failure (162). This 2-4% risk for 
AEs within the first month post-CABG is relatively high, especially considering the good long-term 
survival of these patients with a 5 year-, 15 year-, 25 year- and 35 year survival of 86% , 48% 19% 
and 7% respectively (10).  
There are a number of risk stratification tools available to risk stratify patients undergoing CABG 
surgery. These risk stratification tools are typically derived from large epidemiological datasets 
that indicate factors that affect clinical outcomes. These risk stratification tools use measures 
that can be broadly categorised into: 1. clinical status (including past medical history), 2. 
modifiable risk factors, and 3. non-modifiable risk factors. Clinical status includes past medical 
history, disease severity and operative urgency alongside symptom/disease severity. This 
includes the Canadian Cardiovascular Society (CCS) score of angina severity and the New York 
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Heart Association (NYHA) dyspnoea score (168, 169). The modifiable factors include smoking 
status and BMI (169). Non-modifiable risk factors include age and sex and past medical history 
(169).  All of which negatively affect general, cardiac and vascular health. However, it remains a 
challenge to develop a valid risk stratification tool that performs accurately across the spectrum 
of low-, intermediate-, and high-risk patients (45, 170-174). The two most commonly utilized 
tools in clinical practice are the Society for Thoracic Surgeons (STS) score (typically used within 
the United States of America) and the EuroSCORE II risk calculator (most often used within 
Europe) (35). EuroSCORE II focuses mostly on non-modifiable risk factors including age, past 
medical history and clinical status and does not differentiate between cardiac surgical 
procedures/techniques. The STS scoring system is a more in-depth system which includes non-
modifiable risk factors, past medical history and clinical status. The STS scoring system also allows 
clinicians to differentiate between surgical procedures (169).  
The ability of both the EuroSCORE II and STS to predict risk has been extensively investigated. A 
large meta-analysis comparing EuroSCORE II and STS, comparing the predictive ability of 22 
studies was undertaken. They found that EuroSCORE II and STS scored comparatively (with a 
summary difference in AUC of 0.00) and were both able to predict risk in patients undergoing 
CABG surgery (169). This meta-analysis also found EuroSCORE II outperformed STS in respect to 
calibration (O:E ratio 0.94 and 0.75 respectively), whereas the STS outperformed EuroSCORE II in 
discrimination (AUC: 0.75 and 0.73 respectively) (169). Epidemiological-derived datasets have 
been demonstrated to be unable to predict risk of sudden cardiac death (174). Importantly, it 
has also been demonstrated that 22% of 215 participants investigated with coronary Computed 
Tomography (CT) were demonstrated to have significant coronary artery atherosclerosis (174). 
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Of these, thirteen (25%) and 30 (58%) with significant stenosis were classified into National 
Cholesterol Education Program as low risk and mild coronary calcification respectively (174). This 
highlights the under-performance of epidemiology-derived datasets. Epidemiological-derived 
datasets may also be unable to predict risk in low and moderate risk patients (170-175). Taken 
together, this highlights the imprecision in risk stratification using epidemiological models. 
Similarly, risk stratification tools rarely measure endothelial-protective factors such as exercise 
and diet (14, 15). This highlights the need to investigate the vascular health of individual patients 
thereby allowing a more personalized and accurate risk score. This may be achieved through 
measuring endothelial function as a surrogate of vascular health in these groups. It has previously 
been demonstrated that endothelial function has a profound effect on outcomes and survival in 
healthy individuals, those with cardiovascular disease (CVD) and those undergoing cardiac 
surgery (42, 109, 176). 
Endothelial Function as a Risk Predictor 
The importance of measuring endothelial function as a method to predict risk of AEs was first 
established using invasive quantitative angiography. This was performed first in combination 
with the endothelium-dependent vasodilator acetylcholine (ACh). Schachinger et al (2000) 
demonstrated patients who demonstrate coronary artery constriction in response to ACh 
infusion or cold pressor test had a significantly increased risk of incidence of cardiovascular 
disease (p=0.09 and p=<0.01 respectively). Events defined as cardiovascular death, acute 
coronary syndrome, MI, PCI or CABG, ischaemic stroke or peripheral revascularization. These 
patients also had a blunted response to both increased blood flow (p=<0.01) and intracoronary 
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infusion of nitroglycerin (p= 0.01)  (42). This work was further supported by Suwaidi et al (2000) 
who found that severe endothelial dysfunction in the absence of obstructive coronary artery 
disease is associated with an increased risk of cardiac events (65). Events defined as MI, 
percutaneous or surgical revascularization or cardiovascular death. Quantitative angiography in 
response to pharmacological (ACh) or physiological (cold pressor test) stimulation became the 
gold standard in measuring coronary artery endothelial function (42, 65). Schindler et al (2005) 
investigated myocardial blood flow (MBF) throughout the CPT using Positron Emission 
Tomography (PET) (52). Adverse events were defined as cardiovascular death, acute coronary 
syndrome, MI, PCI, CABG, ischaemic stroke or peripheral revascularistion. They found that, in 
patients with normal coronary angiograms, impaired increase in MFB is associated with an 
increased risk of developing cardiovascular events in patients undergoing diagnostic cardiac 









Table 12) Summary table of studies investigating the predictive capacity of endothelial function 
to predict risk. 









CPT1 and ACh2 
CVD death, ACS4, 
MI, CABG, stroke, 
peripheral 
revascularisation 
7.7 years Significant difference 
in AE vs non-AE 
Groups 
ACh: P: 0.009 
CPT: P: <0.001 
Suwaidi (65) Mild CAD5 Quantitative 
angiography 
and CPT1 
MI, PCI, surgical 
revascularization 
2 years Significant difference 
in AE vs non-AE 
groups P: <0.05 
Schindler (52) Mild CAD5 Myocardial 




CVD deaths, MI, 
PCI, CABG, stroke, 
peripheral 
revascularasiation 
5.5 years Significant difference 
in AE vs non-AE 
groups P:0.033 log-
rank 
1 Cold Pressor Test, 2 Acetylcholine, 3Positron emission tomography, 4 Acute coronary syndrome, 
5 Coronary artery disease 
Clinical utility of risk prediction and issues with inaccurate risk prediction 
Accurate risk prediction is key to all areas of healthcare from individual clinician and patient 
decision making to service planning and evaluation (177, 178). A risk prediction tool has to be 
sensitive, specific and reproducible (179, 180). The sensitivity of a test is the ability of a test to 
identify true positives within a dataset. In the context of surgical risk prediction, this is the 
number of participants that are accurately identified as being “high risk”. These are also referred 
to as “true positives”. The specificity of a test is the ability to identify true negatives within a 
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dataset. In the context of surgical risk prediction, this is the ability to correctly identify patients 
that are low risk.  
The implications of risk prediction can be categorised in to three categories. One, informed 
consent, two the level of care and three four service planning.  
Informed consent  
Accurate risk prediction is key in informed consent. First, a core tenant of clinical decision making 
is the quality and accuracy of the data used to make that decision. This is a collaborative process 
between clinicians, patients and their friends or relatives. This is reliant upon both parties making 
a decision based on accurate and reliable information (179). This is a fundamental tenant of 
informed consent. If risk prediction tools are inaccurate, this means decision making is 
fundamentally flawed (180). Second, a key part of the informed consent process is ensuring that 
language and concepts are understood by everyone involved including the patients and their 
families. The majority of evidence-based practice is reliant upon complex statistical analysis 
which is often difficult to communicate to laypersons. However describing adverse events as a 
frequency of total interventions undertaken may be easier to communicate (180). 
Levels of care 
A second key consequence of risk prediction is offering appropriate evidence-based practice and 
level of care/intervention for each individual and allowing a personalised patient-centered 
approach to risk and care for each individual. The ability to accurately identify patients that are 
at an increased risk is important in all areas of decision making. The ability to identify high-risk 
patients means that a more appropriate treatment can be undertaken. This may mean offering 
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more aggressive interventions thereby reducing risk. If these patients are not identified, this may 
mean “under treating” these patients. This may mean that they experience more events (181). 
Similarly if a patient is considered to be unacceptably high risk for surgical intervention, this may 
mean that they can undergo a more conservative method of treatment (181).  If patients are 
investigated and found to be very low-risk, this may mean that they can undergo a more 
conservative management thereby avoiding the inherent risks associated with surgical 
intervention (181). This avoids the risk of “over-treating” patients who are sufficiently low risk to 
undergo more conservative management. This may mean that patients who are at an increased 
risk may be identified and may further identify key targets for optimisation such as cardiovascular 
fitness, smoking cessation or optimal medical management (182-186) .  
Service planning 
As discussed above, risk prediction tools are key in decision making for both individuals and 
clinicians, however risk prediction tools also play a key role in service planning and performance 
analysis. The identification of the highest risk individuals may allow for extensive pre-planning 
such as further tests and patient optimisation and ensuring that the highest-risk patients are 
cared for by highly-specialist. This may require a combined approach through multiple specialists 
or through care in a specialist tertiary referral center (181). The identification of higher risk 
patients can also allow the safe and effective management of patients including the pre-planning 
of those that are likely to require extended Intensive Care Unit stay (180).  
Service auditing 
The utilisation and publication of outcome data for individual surgeons and surgical units allows 
for external auditing. This allows the comparison with other individuals and institutions to ensure 
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that outcomes fall within defined parameters. If individuals or institutions fall outside of 
acceptale parameter, it may identify a need for further training or service planning (181).   
Endothelial Function and Surgical Risk 
Endothelial function has been demonstrated to predict risk of AEs in both non-diseased and a 
variety of diseased groups (42, 45, 187). There are a small number of studies that have 
investigated endothelial function as a method to predict risk in surgical patients. Saito et al (2018) 
investigated Reactive Hyperemia Peripheral Arterial Tonometry (RH-PAT) in 197 patients who 
underwent cardiac surgery (188). It has previously been demonstrated that an RHI <1.67 was an 
indicator of endothelial dysfunction (188). In this group, RHI ≤1.64 had significantly more AEs 
than those with an RHI >1.64. Multiple regression analysis also demonstrated that the number 
of surgical procedures together with an RHI  ≤1.64 as significant predictors of AEs (188). Similarly, 
McIlroy et al (2013) investigated RH-PAT in 238 subjects undergoing intermediate to high-risk 
non-cardiac surgery. They found endothelial dysfunction investigated via RH-PAT provided a 
limited discrimination for identifying subjects with myocardial injury after non-cardiac surgery 
(MINS) (ROCAUC 0.60, 95% CI – 0.47-0.73) (189). An RHI of ≤1.22 provided a sensitivity of 31% and 
specificity of 96% with a positive diagnostic likelihood of 8.0. Endothelial function was also a 
potent predictor of MINS (OR 11.2, 95% CI: 4.1-30.5, p=0.001) (189). They also found that RH-
PAT combined with Lee index (a prospective validated model to predict cardiac risk in surgical 
patients) improved predictive capacity over Lee Index alone (c statistic 0.69 vs 0.77 respectively. 
Integrated discrimination improvement 0.11 p=0.003) (189). However, the same group also 
investigated RH-PAT in 218 participants undergoing intermediate or high-risk non-cardiac 
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surgery. They investigated renal dysfunction/failure as a primary endpoint and found RH-PAT did 
not predict risk of renal dysfunction/failure in this patient group (190). There are also a small 
number of studies that have investigated the ability of Flow Mediated Dilation to predict risk in 
a variety of surgical patients. Firstly, Gokce et al (2002) investigated endothelial function via Flow 
Mediated Dilation (FMD) in 187 patients undergoing vascular surgery. They followed-up patients 
for 30 days post-operatively for incidence of AEs and survival. They found FMD was significantly 
lower in patients who had AE(s) in the 30-day post-operative period (4.9±3.1 vs 7.3±5% 
respectively: p=<0.001) whereas endothelium-independent vasodilation to nitroglycerin was not 
significantly different in this group (191). Suggesting a normal functioning VSMC in the context 
of a dysfunctional endothelium. FMD was also shown to independently predict risk of Aes in this 
group (p=0.01). When FMD cut-off was defined as 8.1%, FMD had a 95% sensitivity, 37% 
specificity and a 98% negative predictive value (191). Similarly, Schier et al (2012) investigated 
Brachial Artery Reactivity Testing (BART) in 63 patients undergoing major thoracic surgery. 
Patients who demonstrated a “low” FMD (<11.5%) had a significantly higher incidence of post-
operative complications (54% vs 30% p=<0.001) (192). Taken together, this may suggest that non-
invasive measures of endothelial function may be predictive of Aes and survival in patients 
undergoing surgical procedures. This highlights the ability of non-invasive measures of 
endothelial function to predict risk in both cardiac and non-cardiac surgery  
 
Carotid Artery Reactivity Testing 
As discussed above, although a number of measures have shown some potential prognostic 
benefit, these are broadly are prohibitively expensive or investigated non-invasively using 
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peripheral arteries (14, 42). A significant limitation in using peripheral arteries as a surrogate of 
coronary artery endothelial function is the dissimilarity in both structure and function in 
peripheral vs central arteries. This is reviewed extensively within the “Background” section of the 
PhD and in a review article written as part of this PhD (14). The carotid arteries may be uniquely 
placed to offer an easily accessible central artery with both structural and functional similarities 
to the coronary arteries. This was first investigated by Rubenfire et al (2000) (109) who found 
that, in participants with no history of cardiovascular disease, these participants demonstrated a 
carotid artery dilation in response to the SNS stimulus. Whereas, in high-risk participants the 
carotid artery response was attenuated and in those with significant coronary artery disease, 
participants demonstrate a paradoxical constriction of the carotid arteries similar to that in the 
coronary arteries (109). To further investigate this, Van Mil et al (2018) investigated the 
relationship between carotid artery diameter measured using vascular ultrasound and left 
anterior descending artery blood velocity measured using transthoracic doppler in 33 healthy 
individuals. They found a moderate correlation between carotid artery diameter and LAD artery 
blood velocity (r=0.486, and 0.402 respectively) (112). This led them to then investigate carotid 
artery reactivity as a method of predicting risk in patients with PAD. They found that the 
“constrictor” group had a 4.1-fold increased risk in CV events and a 2.0-fold increased risk in 
disease progression when compared to the “dilation” group (54). This was the first study to 
investigate CAR% as a method to predict risk in clinical populations.  
Both Rubenfire et al (2000) and Van Mil et al (2018) have demonstrated that carotid artery 
response can predict risk of Aes in patients with cardiovascular disease and those with PAD. This 
therefore led to us to use CAR% as a method to investigate endothelial function in patients with 
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central (coronary) artery disease undergoing isolated CABG or combined CABG combined with 
valve surgery. Our hypothesis was that first, CAR% predicts the short-term (30 day) incidence of 
AE’s in patient’s post-CABG surgery and second, that CAR% better predicted risk than the 
European EuroSCORE II risk calculation tool.  
6.8. Methods 
Progress Framework 
This research project was reported within the PROGnosis RESearch Stratergy (PROGRESS) 
framework (193). This is a conceptual framework developed collaboratively by experts in 
prognostic research. This is developed to outline the importance of prognostic studies and to 
provide a framework for the development of prognostic studies, requirements when designing 
and undertaking prognostic research studies and the multiple phases employed in prognostic 
research. This is outlined in PROGRESS Framework 2 – Prognostic Factors. This describes the 
process from model development, model validation and finally investigating the impact of the 
prognostic model on research and clinical outcomes (165). When undertaking prognostic 
research, it is key that factors are investigated in participants with a given start point, in this case 
patients with CABG plus or minus valve surgery. This has to have specific, clinically relevant 
endpoints. The endpoints are discussed within the “Methods” section of this chapter. It is also 
key to clearly define and consider the limitations of this study as well as prognostic research more 
broadly including publication bias, reporting bias and adequate statistical analysis.  
A key consideration in the PROGRESS framework is prognostic research as a process, rather than 
as a single study. This therefore describes PROGRESS research in three phases (166). First, in 
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model development, second in the internal and external validation of the tool and finally by 
investigating the impact of this tool in clinical practice. The PROGRESS framework also requires 
the development using a large dataset, based on a study protocol with sound statistical planning 
and finally to be validated in independent datasets obtained from different locations. This study 
can be considered as an early first step or pilot study. As discussed throughout this thesis, there 
are key future steps required to fully investigate the predictive capacity of this test.  
Study Design 
A longitudinal observational study design was employed. All participants are identified, recruited 
and undergo testing prior to surgery. All participants are then followed-up post-operatively for a 
30-day period to investigate if CAR% predicts risk in CABG patients.   
Ethical Approval 
Ethical approval was sought and gained through NHS ethics committee, and governance approval 
from Health Research committee. Reviewed by the North West – Liverpool Central Research 
Ethics Committee on 28/6/17 (17/NW/0347).  
Public and Participant Engagement 
The impact of public and patient involvement (PPI) in the development of clinical trials has been 
demonstrated to improve enrolment, quality, relevance and uptake of research (194). The study 
was therefore developed in collaboration with clinicians, managers and the Service Users 
Research Endeavour (SURE) group. The SURE group are a group of patients and their family 
members responsible for patient advocacy in research throughout Merseyside. The project was 
 114 
also developed in collaboration with service managers at LHCH to maximize recruitment whilst 
minimizing impact to clinical services.  
6.9. Study Setting 
Recruitment was undertaken at the Liverpool Heart and Chest Hospital NHS Foundation Trust 
(LHCH). All participants were identified as requiring Coronary Artery Bypass Graft (CABG) surgery 
or CABG combined with Valve surgery by clinicians at LHCH. 
Participants 
Eligibility 
 We excluded participants who had CABG surgery combined with other forms of major surgery 
such as aortic root surgery as this would skew the risk of AE’s of during surgery and in the post-
operative course. We excluded patients who had undergone carotid artery endarterectomy, 
carotid artery surgery or with known or suspected Raynaud’s syndrome. We also excluded those 
below the age of 18 or those who cannot give consent. This is in line with previously published 
research (43, 54, 130).  
Participant Identification 
Participants were recruited through both the outpatient and inpatient departments at LHCH. 
Participants were recruited initially through the outpatient department at LHCH. Participants 
received a participant information sheet at least 24 hours prior to testing. The use of outpatient 
clinics limited recruitment due to practical considerations and availability. Therefore, recruitment 
was subsequently expanded to also include inpatients at LHCH. Paper consent forms were kept 




The research protocol was undertaken in a temperature and light-controlled room. All 
participants were asked to lay supine for at least five minutes prior to testing as per previously 
published research and guidelines (49, 54, 130). Participants were also asked to abstain from 
food or drink known to affect endothelial/SNS function, although they were allowed to eat. This 
was in-line with guidelines for investigating endothelial function and previously published 
research (54, 130). Although medication was not altered. The medication was not recorded as 
this is recorded on a separate tab within the electronic patient system and access was not given.   
Data Sources 
The past medical history, angina status (Canadian Cardiovascular Society score) and dyspnoea 
status (NYHA classification) were recorded for each participant prior to testing. This was in-line 
with National Institute for Cardiovascular Research (NICOR), National Adult Cardiac Surgery Audit 
(NACSA) dataset. This is detailed in the “Participant Follow Up” section below.   
Carotid Artery Ultrasound alongside the Cold Pressor Test was undertaken as per the Methods 
section of this thesis. The carotid artery diameter alongside RBC velocity were measured non-
invasively using the left common carotid artery imaged via ultrasound. Participants underwent 
the cold pressor test including a one minute “baseline” recording, two minutes with the left hand 
submersed in water at 4°C for two minutes. Due to practical considerations, the submersion time 
for the hand during the CPT was reduced to two, rather than three minutes. This maintained 
patient safety whilst also ensuring sufficient SNS stimulation (54). In our study investigating CAR% 
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in healthy participants, alongside other studies have all shown that there is a statistically 
significant change in both blood pressure and CAR%. In our first study investigating CAR%, peak 
MAP occurred at 112±38 seconds. The peak CAR% occurred at 92±43 seconds. Therefore, an 
immersion time of 2 minutes was considered sufficient to achieve peak CAR%.  
Data quality 
Scan acquisition 
An area distal to the carotid bulb is used for scan acquisition. An area adjacent to, but not 
including the carotid bulb is used. The largest region of interest possible is used. This is at least 
one third of the entire segment visualised. This ensured that data is representative of the entire 
arterial segment.  
Scan analysis 
All scans were analysed blinded to avoid bias in analysis. All scans were also analysed 
independently by two researchers to ensure quality and further reduce the probability of bias. 
As all scans were only undertaken once, it was not possible to measure between-scan variation.  
Clinical data collection 
Patient data was collected from electronic patient records systems. The use of electronic patient 
records alongside specific post-operative protocols ensured that data was up to date and 
accurate. There were no “missing” datapoints. A random selection of 30 participants were 
selected and the data input and follow-up was checked independently by a second researcher 
using the patient medical records. This ensured accuracy and validity in data collection.  
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Participant Follow Up 
To enable participant follow-up, all participants included within the trial were added to an online 
database on the Electronic Patient Records (EPR) system at LHCH. This allowed the accurate 
follow-up of each participant involved in the trial. All participants were followed-up using the 
secure online EPR system. The pre-operative risk factors, intra-operative surgical course and 30-
day post-operative outcomes were collected for each participant. This was reflective of the 
National Adult Cardiac Surgery Audit (NACSA) dataset (version 5.1.0) collated by the National 
Institute for Cardiovascular Outcomes Research (NICOR). The dataset is developed by NICOR with 
clinical direction and strategy provided by the Society for Cardiothoracic Surgeons (SCTS). The 
NACSA dataset collates known pre-operative risk factors, past medical history and clinical status 
alongside known and suspected intra-operative and post-operative surgery-related events.  
All participants were followed-up for a period of at least 30 days post-operatively or throughout 
their hospital admission if this extended beyond that. Participants who were re-admitted post-
operatively were also followed-up throughout the subsequent hospital admission. This was in 
line with England’s combined Hospital Episode Statistics and Office of National Statistics (HES-
ONS) definition of perioperative-associated cause of death and NICOR NACSA datasets (195). The 
primary endpoint is adverse events as defined below within the 30-day post-operative period or 
within the same hospital admission.  
Adverse Post-Operative Events 
Adverse post-operative events collected were: Death within 30 days (or same admission) of 
surgery, cardiovascular events and neurological events. The cardiovascular events defined are as 
new-onset post-operative angina, myocardial infarction (MI), or new graft failure. The 
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neurological complications are defined as new post-operative transient ischaemic attack (TIA) or 
stroke. All events are associated with plaque rupture events. These definitions of adverse events 
are derived from the current NASCA NICOR dataset definitions of adult cardiac surgery-related 
adverse events.  
All pseudo-anonymized electronic data was kept securely on Liverpool John Moores University 
servers. When the complete dataset had been produced and pseudo-anonymized, the accuracy 
and validity of this data was subsequently independently verified by a second member of the 
research team. 
Statistical Analysis 
All data were presented as mean with standard deviation together with median. If there was a 
large difference in mean and median, this suggests that the data may be skewed. The range for 
each variable was also presented to demonstrate the variance within participants. The 
scatterplots are presented in appendix one. All data was first assessed for the “level” of data. 
Nominal data was assessed using cross-tabulations including Chi Squared and Fischers exact test. 
Ordinal data such as ejection fraction typically used non-parametric statistical analysis. Interval 
continuous data such as BMI were assessed using correlative analysis. The kurtosis and skewness 
was measured using a D’ Agostino-Pearson goodness-of-fit test. If there were two variables and 
the data was normality distributed, a t test was used. If the data was non-normally distributed, 
the non-parametric equivalent was used. If there were more than two variables, a one-way 
ANOVA was used. If the data was non-normally distributed, the non-parametric equivalent was 
used. If the data was binary, a Chi-squared and Fischers exact test were used (95% confidence 
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interval). Whereas the Chi-squared test assumes a large dataset and therefore provides an 
approximation, the fischers exact test provides an exact value and is therefore more powerful in 
datasets with less than five counts (134). If the data was continuous, normality testing was first 
performed using D’ Agostino-Pearson goodness-of-fit testing. A Pearson correlation was used is 
the data was normally distributed. If it was non-normally distributed, a Spearman correlation was 
used. Statistical significance is defined as a P<0.05.  
Study Power Calculation 
Assuming 5% significance, and given the difference in AEs we observed of 12.5%, we have a 
power of 50.2% to draw the conclusions in this thesis. A future, fully powered study, is needed 
to confirm the results in this work. 
6.10. Results 
The results were divided into four sections. First, a description of the characteristics of the 
population. Second, a comparison of participants who did, and did not have post-operative AEs. 
Third, a comparison of participants dichotomized based on the median CAR%. Finally, logistic 
regression analysis to investigate if EuroSCORE II and CAR% predict post-operative AEs in this 
group.  
Consort Diagram 
A CONSORT diagram of participants assessed, approached and recruited in to this study. As all 
follow-up used patient medical records, there was no loss to follow-up. A diagram describing 
follow-up is therefore not included. In this study, only approximately 45% of participants in the 
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eligible pool were recruited. This is due to a lack of availability in outpatient clinics within the 
trust. This is detailed further within the discussion section of this chapter.  
Figure 8) A CONSORT diagram of recruitment process, enrolment and outcomes.  
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Adverse Events Group Characteristics 
Ten participants experienced AEs post-operatively (as defined in the “Methods” section of this 
chapter). The participant characteristics are presented in Table 13 and 14. There was no 
statistically significant difference (including age, BMI, symptom severity or clinical risk score) in 
patients that did and did not have AEs. There was no statistically significant difference in baseline 
diameter or CAR% in these groups.  
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Table 13) Group characteristics of participants when grouped according to the presence or absence of Adverse Events. N=95. 
Independent samples T Test.  
  Adverse Events  














69 45  
(41-86) 
10 70 33 
(50-83) 




















2 3 (1-4) 1.4 2 3  
(1-3) 





2 IQR 3  
(0-4) 
1.3 1 3 
(1-3) 







1.17 2.27 6.53  
(0.53-7.03) 




1: New York Heart Association of Heart Failure symptom classification 
2: Canadian Cardiology Society Angina classification 
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Table 14) Carotid artery diameter measurements in the total group as well as those in AE and non-AE groups.  N=95. Independent 
samples T Test performed.  
 
1: Average change in diameter across the CPT 
  
  Adverse Events  















1.10 0.77 0.29 
(0.59-0.88) 







0.11 0.78 0.25 
(0.61-0.86) 








2.97 0.68 8.63 
(-3.87-4.76) 




The presence of risk factors and disease severity in AE and non-AE groups are presented in (Table 
15 and 16 respectively). There was no statistically significant difference in measures of disease 
severity or risk factors in the AE and non-AE groups (Table 15). There was a statistically significant 
difference in the ratio of patients who had on-pump vs off-pump surgery in the AE vs non-AE 
groups (Table 16). A larger proportion of patients who had AEs had off-pump CABG surgery. (Χ2a: 
0.02 Fb: 0.04).   
Table 15) Family History and known risk factors in AE and non-AE groups. Fischers exact and Chi 
Squared test.  
 Adverse Events  



















Fb:  0.68 
Family history of CVD 7 3 3 50 Χ2a:0.11 
Fb:  0.10 
Hypercholesteremia 7 3 59 27 Χ2a:>0.99 
Fb: 0.93 
Peripheral vessel disease 2 8 10 76 Χ2a:0.16 
Fb: 0.20 
Previous MI 4 6 26 57 Χ2a:0.58 
Fb: 0.72 
Previous PCI 2 8 19 67 Χ2a:0.80 
Fb:>0.99 
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Diabetes  1 9 30 56 Χ2a:0.11 
Fb:0.16 
Pulmonary disease 2 8 9 77 Χ2a:0.31 
Fb: 0.32 





Table 16) Effect of disease severity in adverse event and non-AE groups. If the variable is binary 
a Chi Squared and fischers exact test is used. If there are two variables, a t test is used. If there 
are more than 2 variables, a one-way ANOVA is used.  
 Adverse Events  




Coronary vessel disease1 
One vessel >50% 
Two vessels >50% 






















Ejection fraction category3 
Good (LVEF >50%) 
Fair (LVEF 30-50%) 















































Cardiopulmonary Bypass Time - - P: 0.08 
Cross Clamp Time - - P: 0.22 
Length of Stay - - P: 0.03 
ICU Stay - - P: <0.01 
 
1 Diagnosed via angiography, CT or MRI.  
2 Left main stem disease greater than 50% 
3 Ejection fraction categories using NICOR dataset and taken from medical notes.  
a: Chi Squared  
b: Fischers exact test 
  
 129 
Adverse Events and EuroSCORE II 
The averaged multivariable risk score (EuroSCORE II) was compared in the AE and non-AE groups. 
This was presented in Figure 9. There was no statistically significant difference in EuroSCORE II 
between the AE and non-AE groups.  
Figure 9) A comparison of EuroSCORE II score in participants in AE and non-AE groups. 
Independent samples t test used. AE is participants that suffered an adverse event as defined in 
the methods section of this chapter.  
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Demographics in participants dichotomized according to median CAR% 
The primary hypothesis of this study was that patients who have post-operative AEs have 
significantly poorer endothelial function. The participant were therefore dichotomized according 
to their CAR% to the CPT. There are currently no studies that have characterized what is a normal 
and healthy responses versus a response demonstrating significant endothelial function. The 
participants were dichotomized in to the top and bottom 50% according to median CAR%. The 
data was skewed with a large range, therefore both mean and median are provided. The effect 
of group characteristics, and measures of carotid artery diameter on CAR% were investigated. 
The participants were first grouped into those greater than and less than median CAR%. Median 
CAR% was 1.96%. This data was presented in Table 17. There was no statistically significant 
difference in group characteristics when participants are grouped according to median CAR% 
response. There was a statistically significant difference in EuroSCORE II score (P: 0.01) and CAR% 
(P: <0.01) in these groups.  
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Table 17) Characteristics of participants when separated into those with greater than, and less than median CAR% (1.96%) 
 Median CAR% 
(1.96%) 
<median >median 



















- 2 3 (1-3) - 0.57 
CCS status2 
(1-4) 
2 4  
(0-4) 





























1: New York Heart Association of Heart Failure symptom classification 
2: Canadian Cardiology Society Angina classification 
3: Average change in diameter across the CPT 
  
EuroSCORE II and CAR% in participants dichotomized according to CAR%.  
Figure 10) A comparison of EuroSCORE II and CAR% in participants when they are dichotomized 
according to their CAR%. A) There is a statistically significant difference in EuroSCORE II when 
participants are dichotomized according to their median CAR% response (p: 0.001). Independent 
samples t test. B) There is a statistically significant in CAR% when participants are dichotomized 




The relationship between family history, risk factors and disease severity were then investigated 
in participants when they are grouped according to median CAR%. This was presented in Table 
18 and 19 respectively. There was no statistically significant difference in measures of disease 
severity or risk factors in participants when grouped according to their median CAR% response.  
Table 18) Effect of Family History and known risk factors in those with a CAR% above, and 
below median CAR%. Chi Squared and Fischers exact test performed.  
 CAR  










Gender Female: 12 Male: 16 Female:6 Male: 41 Χ2a: 0.13 
Fb: 0.19 
Family history of CVD 22 26 21 26 Χ2a: 0.91 
Fb: >0.99 
Hypercholesteremia 31 17 35 12 Χ2a: 0.30 
Fb: 0.40 
Peripheral vessel disease 8 40 4 43 Χ2a: 0.23 
Fb: 0.36 
Previous MI 20 28 13 34 Χ2a: 0.20 
Fb: 0.15 
Previous PCI 12 36 9 38 Χ2a: 0.50 
Fb: 0.62 
Diabetes  13 35 18 29 Χ2a: 0.24 
Fb: 0.28 
Pulmonary disease 6 42 5 42 Χ2a: 0.78 
Fb: >0.99 




Table 19) Effect of disease severity in those with a CAR% above, or below median. If the 
variable is binary a Chi Squared and fischers exact test is used. If there are two variables, a t test 
is used. If there are more than 2 variables, a one-way ANOVA is used.  
 Median CAR  
P Value Bottom 50% 
(count) 
Top 50%  
(count) 
Coronary vessel disease1 
One vessel >50% 
Two vessels >50% 






















Ejection fraction category2 
Good (LVEF >50%) 
Fair (LVEF 30-50%) 






































1 Diagnosed via angiography, CT or MRI.  
2 Left Main Stem Disease greater than 50% 
3 Ejection Fraction categories using NICOR dataset and taken from medical notes.  
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a: Chi Squared  
b: Fischers exact test 
CAR% vs EuroSCORE II 
 
The multivariable risk score (EuroSCORE II) on endothelial function (CAR%) were then 
investigated. EuroSCORE II is the gold-standard score used clinically to predict risk of mortality 
in patients undergoing cardiac surgery. This was presented in Figure 11. There was a weak 
inverse correlation between EuroSCORE II and CAR% (P: 0.011 r: -0.259) 
Figure 11) Relationship between CAR% and EuroSCORE II. “Positive AE” defined as participants 
who suffered an adverse-event post-operatively. Pearson correlation performed.  
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Adverse Events in Participants Grouped According to Median CAR% 
The number of AEs were then investigated in participants when dichotomized according to 
median CAR%. This was presented in Table 20. There was no significant difference in the number 
of AEs in the two groups. It should be noted that there were only a small number of AEs. Chi-
Squared value is an approximation and performs more poorly in datasets with less than 5 counts 
(134). Fischers exact value is therefore also provided. 
Table 20) Number of AEs in dichotomized participants. Chi Squared and Fischers exact test 
performed. A one-tailed analysis was performed with a 95% confidence interval.  




Top 50% 45 2 
Bottom 50% 40 8 
P value Χ2a:0.05 
Fb: 0.09 
a Chi Squared 
b Fischers Exact test 
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Predictive capacity testing 
The presence of outliers was first investigated to normalize the dataset. To investigate the 
primary and secondary hypotheses. The ability of EuroSCORE II (gold standard) and CAR% to 
predict post-operative AEs were investigated. This was investigated using non-linear regression 
analysis. The impact of CAR% on the predictive capacity of EuroSCORE II was then investigated. 





The sum-of-squares calculation (a study of variance within regression analysis) is highly sensitive 
to outliers (196). A ROUT analysis was undertaken first to identify outliers within the dataset. A 
ROUT analysis was performed as outliers within non-linear regression analysis is highly sensitive 
to outliers. Outliers within these datasets can dominate the sum-of-square analysis calculation, 
thereby skewing both logistic regression and multivariable logistic regression analysis (196). 
Based on a 1% False Discovery Rate (FDR), 3 outliers were identified. This was presented in Figure 
12. These participants had a EuroSCORE II score of 5.28%, 6.57% and 7.03% respectively.   
Figure 12) ROUT analysis Investigating the presence of outliers within the dataset. This identified 





Predictive Capacity of EuroSCORE II 
The ability of EuroSCORE II to predict risk was then investigated. EuroSCORE II is the current gold 
standard and is used in clinical practice to predict AEs in cardiac surgery. This was presented in 
Figure 13.  In this study, EuroSCORE II did not predict risk of AEs.  




Predictive Capacity of CAR% 
The ability of CAR% to predict risk was then investigated. This is presented in Figure 14. In this 
group, CAR% does not predict post-operative AEs.  
Figure 14) Logistic regression analysis of the ability of CAR% to predict AEs in patients 





Multiple Logistic Regression Analysis of Combined CAR% and EuroSCORE II 
The combined ability of EuroSCORE II (gold standard) and CAR% to predict AEs was then 
investigated. A multivariable logistic regression analysis method was used. This was presented in 
Figure 15. EuroSCORE II combined with CAR% did not predict risk in this group.  
Figure 15) Multiple logistic regression analysis of the ability of CAR% combined with EuroSCORE 





Whole Group Characteristics  
This study included a small number of patients, therefore this study was first compared to one of 
the largest multi-site studies involving approximately 32000 participants undergoing CABG 
surgery between 2012 and 2014 (197). In our study, participants were on average 5.1 years older 
than that of the comparable study (69 years in our study vs 64 years). Our study had a smaller 
percentage of participants with 3 vessel disease compared to the larger-scale study (62% in our 
study vs 65.5%). In this study, 28.4% of participants had a CCS angina score of 0, 32% had a CCS 
score of 1-2 and 38% had a CCS score of 3-4. Whereas in the comparable study, 0% had a CCS 
score of 0, 37.5% had a CCS score of 1-2 and 62.5% had a CCS score of 3-4. Taken together, this 
highlighted the relatively low risk profile of the participants included in this study. This may have 
been as a result of predominantly recruiting from the outpatient setting.  
EuroSCORE II 
In this group, EuroSCORE II was not correlated with individual risk factors or disease severity. 
Similarly, EuroSCORE II did not predict risk of cardiovascular or neurovascular AEs or death in this 
study. Although EuroSCORE II is a validated risk-prediction tool and is used clinically, there are a 
number of limitations to using EuroSCORE II to predict post-surgical AEs. First, EuroSCORE II was 
originally designed to predict operative mortality. However it has also been adopted to predict 
AEs (198). Only one patient died within this study, therefore EuroSCORE II was correlated with 
post-operative AEs rather than mortality. A small number of studies have investigated the ability 
of EuroSCORE II to predict postoperative AEs. Ranjan et al (2019) demonstrated that EuroSCORE 
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II can predict post-operative MI (ROCAUC:0.854) but is poorly predictive of stroke (ROCAUC: 0.646). 
This was a larger study of 865 participants with 29 (MI) and 7 (Stroke) events respectively (199). 
They therefore demonstrate good predictive capacity for MI, but poorer predictive ability for 
stroke. Similarly, Biancari et al (2012) found EuroSCORE II was poorly predictive of stroke in 1027 
patients undergoing isolated CABG (ROCAUC: 0.649) (200). The poor ability of EuroSCORE II to 
predict cardiovascular AEs, cerebrovascular AEs and death in our group was therefore in-line with 
previously published research particularly in neurovascular events and would therefore require 
a large number of events to demonstrate a predictive capacity.   
Second, It has been demonstrated previously that EuroSCORE II performs best in moderate risk 
groups, and performs poorly in low-risk and high-risk individuals (201). In our study, when 
outliers were removed (ROUT analysis, Q Rate 1%), mean EuroSCORE II score was 1.56% (0.31%-
4%). In line with previously published work, a EuroSCORE II score of less than 2% are considered 
low-risk and a EuroSCORE II score of less than 1% as very low risk (202). This was therefore a low 
risk group and this finding was in-line with previous studies which have demonstrated that 
EuroSCORE II performs poorly in lower risk  groups (201). 
Third, the EuroSCORE II risk tool was first launched in 2011. There have been a considerable 
number of changes in National Institute for Health and Care Excellence (NICE) guidelines, and an 
increased move towards PCI in this time (203). Similarly, Lebreton et al (2011) also highlighted 
the inability for clinicians to specify the surgical procedures undertaken. The EuroSCORE II tool 
includes the number of procedures undertaken, but not the specific interventions. This is in 
contrast to the STS tool, in which surgical interventions are specified (168). This may mean the 
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STS tool allows a more patient-specific approach to risk stratification and tailoring to higher-risk 
interventions. This may be required to be incorporated into future updates of the EuroSCORE 
tool.  
Finally, EuroSCORE II is a risk prediction tool derived from large datasets and therefore does not 
allow the personalization of risk prediction or the addition of emerging factors which predict AEs 
such as endothelial function. Although EuroSCORE II does include a small number of risk factors 
known to affect endothelial function, this does not include atheroprotective factors such as diet 
and exercise (204, 205). Taken together, EuroSCORE II did not predict risk in this group. This was 
in-line with previous studies within the literature. This may provide further evidence for a 
requirement for further refinement of EuroSCORE II including the ability to specify intervention 
types as well as the inclusion of emerging risk prediction tools including measures of endothelial 
function as a surrogate of vascular health.  
Carotid Artery Response 
Previous studies have demonstrated that CAR% is a strong predictor of disease progression and 
events in PAD patients (54). However, to our knowledge this was the first study investigating if 
CAR% predicts AEs in CABG patients. In this group, CAR% did not predict risk in patients 
undergoing CABG surgery. This may be due to a number of factors.  
First, Endothelial function has been demonstrated to predict risk in cardiovascular disease 
patients. However, measures of endothelial function do not incorporate other factors such as 
past medical history, active infection, critical preoperative status or a recent history of MI. All of 
which affect post-operative outcomes indepenbydent of endothelial function (35, 168, 201). 
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Although these may be influenced by endothelial function, these are not directly incorporated in 
to measures of endothelial function.  
A second key consideration is that CAR% was used as a measure vasomotion as a surrogate of 
systemic endothelial function/health. Although risk prediction has traditionally relied upon 
investigating plaque burden within the coronary arteries, and identifying flow limiting lesions, 
The majority of MIs are caused by non-flow limiting lesions (206). Similarly, a large amount of 
plaque rupture events are asymptomatic in the short-term but may lead to eventual narrowing 
(206). This highlights the importance of identifying high-risk plaque that are vulnerable to rupture 
and are likely to cause ischemia. A number of key markers of high-risk plaque have been 
identified including a large necrotic core, extensive calcification, and macrophage infiltration 
(206, 207), alongside emerging novel CT and ultrasound imaging characteristics (208-210) 
Similarly, a growing body of evidence has found that coronary inflammation measured both 
systemically (plasma biomarkers) and locally predict risk of AEs (108). Recently, Antoniades et al 
(2020) demonstrated that coronary inflammation quantified as perivascular fat attenuation index 
(FAI) improved cardiovascular risk discrimination for all-cause and cardiac mortality when 
compared to current risk factor analysis (smoking, diabetes), extent of coronary atherosclerosis 
and high risk plaque features (108, 211). Taken together, this highlights the complex 
multifactorial nature of plaque rupture events and further highlights the limitations of measuring 
disease burden or systemic endothelial function as a predictor of AEs. 
Third, carotid artery vasomotion is a complex vascular response encompassing the entire length 
of the artery resulting in a three-dimensional constriction or relaxation in response to stimuli. 
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Whereas two-dimensional carotid artery ultrasound measures a small representative segment of 
the entire artery. The quantification of carotid artery response measures the distance between 
proximal and distal walls of the vessel along a single plane.  Although CAR% is relatively simple 
and non-invasive, it may not have been representative of the complex three-dimensional 
response along the entire artery. This was not fully investigated within our study or the literature. 
This was discussed extensively in Chapter 7 of this thesis. Similarly, CAR% was used as a measure 
of vasomotion as a surrogate of endothelial function. Vasomotion is reliant upon vascular 
distensibility. However, it was previously demonstrated that the presence of plaque affects 
vascular distensibility and vasomotion. No obvious plaque was included in the segment of vessel 
scanned as part of this study. Giannattasio et al (2001) demonstrated that carotid artery 
distensibility was significantly lower in both the internal and common carotid artery in the 
presence of plaque when compared to contralateral plaque-free arteries in patients with 
hemodynamically significant unilateral atherosclerosis with >75% occlusion (212). Importantly, 
arterial distensibility was also significantly reduced in the plaque-free common carotid artery if 
the internal carotid artery has plaque >75% (212). This highlight the impact of atherosclerosis on 
arterial distensibility both proximal and distal to the plaque site. This may alter the CAR% 
response in atherosclerotic arteries. Puri et al (2013) demonstrated that coronary atheroma 
volume was associated with endothelium-dependent vasoreactivity independent of clinical 
presentation (213). This is a key consideration as patients undergoing CABG surgery have a large 
variance in the severity and presence of carotid artery atherosclerosis in neurologically 
asymptomatic CABG patients (214). The alteration of distensibility and therefore vasomotion in 
the presence of atherosclerosis may therefore mean that CAR% can only be used in patients 
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without evidence of carotid artery atherosclerosis, although this has not been tested. Taken 
together, CAR%, did not predict risk in this group. This may be as a result of a number of 
considerations in endothelial function as an independent risk prediction tool as well as key 
considerations in the use of CAR% to investigate endothelial function. There are also practical 
considerations and limitations associated with our study. Although CAR% was not clinically useful 
as a risk prediction tool in isolation, it may offer a simplistic and non-invasive tool to measure 
endothelial function which can be incorporated and used along-side tools which measure other 
factors known to predict AEs such as measures of systemic health and clinical status.  
Multivariable Logistic Regression Analysis 
EuroSCORE II alone and CAR% alone did not predict risk. It was then investigated if CAR% as a 
measure of endothelial function added to the predictive ability of EuroSCORE II. When a 
multivariable logistic regression analysis was performed, EuroSCORE II combined with CAR% did 
not predict risk of AEs. However, this did marginally increase the ROCauc. This may be suggestive 
of an improvement. Although in this study, it is not possible to conclusively investigate this. As 
others have investigated CARAUC and CAR90, and demonstrated that these predict risk (115). These 
were also investigated. Both CARAUC and CAR90 do not predict risk in this group (r: 0.364 and 
r:0.454 respectively). Data not shown. This lack of correlation may be due to a number of factors.  
First, there was a weak inverse correlation between EuroSCORE II score and CAR% with patients 
at the highest risk of surgical AEs also having the poorest endothelial function. The correlation 
between EuroSCORE II and CAR% may explain the small improvement in predictive capacity as 
both EuroSCORE II and CAR% did not predict risk. EuroSCORE II incorporates a small number of 
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risk factors which affect endothelial function such as increased age and diabetic status (135), as 
well as factors that may be a marker of endothelial dysfunction such as disease severity, symptom 
severity and presence of PAD (14, 54). The combination of both EuroSCORE II and CAR% may be 
disproportionately weighting risk factors associated with endothelial (dys)function above other 
key factors. To overcome this, in future CAR% may be treated as a multivariable analysis of known 
and suspected factors which affect endothelial function and can then be considered in the 
weighting of risk stratification tools. However, the weighting of individual variables within the 
EuroSCORE II tool are not published. It should also be noted that there are only a small number 
of events within this study. A larger study, including a higher incidence of AEs would first have to 
be investigated and would be more able to identify moderately predictive tools.  
Medical Management/Percutaneous Coronary Intervention 
In this study, ten participants who were first identified as requiring CABG surgery did not undergo 
CABG surgery. These patients were thought to have an unacceptably high risk of AEs or had small 
focal disease and therefore underwent conservative management. In our study, two of the three 
patients who did not undergo CABG surgery due to the high-risk nature demonstrated a negative 
CAR%. Whereas in patients who underwent conservative management (PCI or Medical 
Management (MM)) due to the low severity or sub-clinical coronary artery disease, six of the 
seven patients demonstrated carotid artery dilation. It should be noted that in the medical 
PCI/MM group, the participant with the poorest endothelial function (CAR% -4.57%) had small 
focal disease and therefore opted for PCI. This patient was therefore comparatively very low risk. 
This was an interesting finding suggesting that CAR% may be in agreement with clinical decision 
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making in this group, although this is underpowered. The inability to follow-up these patients 
over a prolonged period of time, and an inability to perform hazard ratio analysis limits 
conclusions in this group, as it is unknown if this was the correct management for these 
individuals. 
Data quality 
A key consideration in any research project is the quality of the data. In this study, there are a 
number of opportunities for limitations in data quality.  
Scan acquisition 
A key consideration in clinical studies involving imaging is in the quality and standardization of 
imagine acquisition and processing. When utilizing the carotid artery in imaging research, it is key 
to try to standardize scan acquisition. In this study, the area distal to the carotid bulb was utilized. 
An area adjacent to, but not including the carotid bulb is utilized. The largest area of Region Of 
Interest was included to ensure scans were representative of the entire arterial segment imaged.  
Scan Analysis 
All scans were interpreted blinded to ensure there was no bias in demonstrating vasoconstriction 
in patients who were at an increased operative risk. All scans were also analysed independently 
by two researchers to ensure quality in scan. As all scans were only undertaken once, the variance 
in scanning could unfortunately not be measured.  
Clinical Data  
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All data collected was taken directly from the patients clinical records. The use of paperless 
medical notes means that there were no “missing” datapoints during the follow-up period. The 
accuracy of the data was also ensured by a second member of the research team. A randomly 
selected sample of ~30 participants were selected and the data input on the follow-up 
spreadsheet was checked against the medical records. This was to ensure the accuracy and 
validity of data extraction.  This was undertaken by a second member of the research team 
independently. As all files are stored electronically, there was no missing data in this study.  
Study Limitations 
There are a number of limitations or considerations associated with our study. Firstly, this study 
involved 95 participants and ten AEs. In logistical regression analysis a further three participants 
(one AE) were removed due to being outliers. Although the number of events per variable were 
acceptable for both linear regression and multivariable analysis, this would likely have been 
underpowered to identify moderately predictive tools. The number of participants is also lower 
than the predicted number of participants required. Due to limitations in recruitment from 
outpatient services, recruitment was expanded to include inpatients. In retrospect, recruitment 
should have included both outpatient and inpatient services from the beginning. Similarly, 
recruitment may have been opened up to multiple study sites to further improve recruitment. 
This may have also increased the variance in demographics and risk profile of participants 
involved in the trial making this more representative of moderate and higher risk patients. 
A second limitation is that EuroSCORE II alone was used. Although EuroSCORE II is current clinical 
practice within the UK, there are a relatively small number of variables included in this that are 
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known to affect endothelial function such as age and diabetic status. The US STS risk tool 
investigates a larger number of variables which are known or suspected to affect endothelial 
function such as exercise tolerance. The STS score could have been compared to both EuroSCORE 
II and CAR% as well as investigating if CAR% improved the predictive capacity of STS. However, 
this was unfeasible as a number of the variables included in the STS score are not routinely 
recorded in the UK. A questionnaire could have also been included which records both athero-
protective (eg exercise) and pro-atherosclerotic (smoking, obesity) risk factors to gain a more 
complete picture of accumulative risk factor profile on endothelial function.  
A third consideration is the effect of menopause on female endothelial function. It has been 
demonstrated previously that there is a reduction in endothelial function in post-menopausal 
women. It is thought that this is as a result of a loss of endothelially-protective estrogen. There 
may also be an improvement in endothelial function associated with hormone replacement 
therapy. A limitation of this study was that, although women were included in the study, we did 
not control for this as a confounding variable. This was also not controlled in previous studies 
which have demonstrated the predictive capacity of endothelial function. However, a larger 
study involving a larger number of participants would allow subset analysis including pre-
menopausal women, post-menopausal women and post-menopausal women receiving hormone 
replacement therapy.  
A fourth consideration is the associated between endothelial function and atrial fibrillation. It 
has previously been reported that poor endothelial function is associated with an 11% increased 
absolute risk and a 5.8-fold relative risk of atrial fibrillation (215). It is thought this is caused by a 
 153 
number of inter-related mechanisms including altered hemodynamics, altered shear stress 
affecting vascular endothelial cells, a reduced nitric oxide bioavailablilty, an increased reactive 
oxygen species, inflammation and abnormalities in the rennin-angiotensin axis (215). AF has also 
been associated with an increased risk of adverse events (216, 217). This therefore makes the 
increased risk of AF associated with poor endothelial function and therefore the increased risk of 
adverse events a potential confounding variable. In our study we included patients that are 
currently in AF. However, we did not consider AF a post-operative adverse event. It was thought 
that, as a significant number of CABG patients are in AF. It was key that, if CAR% was able to 
predict risk, it should do so in a clinically representative sample of CABG patients.  
A fifth consideration was the inability to standardize the time of testing. It has been 
demonstrated previously that point in the circadian rhythm (218) and menstrual cycle (219) 
affect endothelial function. It was not possible to standardize the time of testing, point in the 
menstrual cycle or peri/post-menopause when undertaking testing in clinical populations 
recruited directly from NHS sites. Similarly, as patients were typically tested within a short time 
period after diagnosis. This may mean that patients were already under a considerable amount 
of stress and therefore this may alter SNS response to the CPT.  However again, it was impractical 
to standardize testing after a defined period post-diagnosis. This test has also been previously 
demonstrated previously to predict AEs and outcomes in PAD patients (54). It was therefore key 
that if CAR% does improve risk prediction, it must do so in a clinical environment and in clinical 
populations.  
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7. Chapter 7: Thesis Conclusions and Future Work 
7.1. Chapter introduction 
This chapter summarizes the findings of this as well as the impact of this thesis on the research 
literature. This further explores key areas for development as well as key steps that have to be 
taken before this method may be used in wider research or in clinical practice.  
7.2. Study Summary 
This thesis incorporated two studies. The first was a mechanistic study investigating the degree 
to which peripheral blood pressure was related to carotid artery diameter change during the 
CAR% test. This study demonstrated that there was no correlation between blood pressure 
response and CAR%, supporting the hypothesis that CAR% is not predominantly driven by 
transmural pressure. These findings therefore added further evidence to the validity of CAR% as 
a measure of endothelial function. The second study investigated the ability of CAR% to predict 
AEs within 30-days of CABG surgery. The results demonstrated that EuroSCORE II and CAR% alone 
did not predict post-operative AEs. However, when adding CAR% to the EuroSCORE II, the 
predictive capacity may have marginally improved, although this was not predictive of AEs. This 
may suggest a benefit in incorporating CAR% into risk prediction tools. A caveat to this is the low 
sample size and event numbers within this study. We cannot conclusively investigate the 
predictive capacity of the CAR% using this study due to the number of events. This therefore 
requires further work including larger studies including more patients and therefore more AEs.  
The present chapter provides an in-depth discussion of the implications of these findings, and 
key areas that require further investigation. The implications are presented in four sections: one. 
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physiological regulation of vasomotion and CAR%. Two, future work in scan acquisition. Three, 
practical considerations for clinical integration and clinical implications of CAR%. Four future 
work and practical considerations and section five brings together the findings of this thesis 
alongside the previous findings within the literature and discussed the incorporation of CAR% 
and the implications on clinical practice.   
Thesis strengths and weaknesses 
7.3. Study Strengths and weaknesses 
The individual strengths and weaknesses of each study have been discussed within each study. 
This section will discuss the strengths and weaknesses of the thesis as a whole.  
Strengths 
This thesis presents the findings from two distinct but inter-related studies. Combined, they 
provide a novel insight in to carotid artery endothelial function in both health and disease. The 
aim of the first study was to better understand the mechanism that regulates the vasomotive 
response to CAR%. The second study investigated endothelial function as a method to predict 
risk in central arterial disease patients undergoing CABG surgery.  
A strength of this thesis is that it included both a mechanistic study to better understand the 
underlying mechanisms which drives a response and second a study which practically 
investigates the clinical utility of this tool, alongside a study in clinical populations. This first study 
added validity to the use of CAR% as a measure of endothelial function whilst also informing on 
the practicalities of undertaking this research in a more easily controlled University environment 
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before this was transitioned in to a clinical environment. It gave further opportunities to develop 
ultrasound techniques as well as problem-solving outside of a busy clinical environment.  
A second strength is in the robustness of the data collected. In study 2, the data was checked for 
accuracy by a second independent researcher. All scans were analysed blinded and checked 
independently by a second researcher. Although these studies did not reach the required number 
of participants, considerable effort was made to ensure data quality of studies individually and 
in the thesis as a whole.   
Weaknesses 
A fundamental limitation in investigating CAR% as a surrogate of endothelial function is that the 
mechanisms regulating vasomotion are incompletely understood. As discussed within the 
background of this thesis, vasomotion is regulated through inter-related mechanisms. CAR% is 
used as a surrogate of endothelial function and although it has been demonstrated previously 
that CAR% is significantly driven by endothelial function and that vasoconstriction in response to 
SNS stimulus is a marker of endothelial dysfunction, the influence each inter-related mechanism 
has on vasomotion is incompletely understood. If CAR% is going to be used as a surrogate 
measure of endothelial function, it is key to elucidate the degree to which endothelial function 
regulates vasomotion. However, this remains challenging because the mechanism of vasomotion 
is regulated by a complex relationship of inter-related mechanisms.  
Similarly, although study 1 provided further evidence that CAR% is predominantly driven by 
endothelially-mediated mechanisms, this study was conducted in just men aged 30-60. Whereas 
study 2 included both men and women and the average age was 69 years old. As part of the 
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effort to improve the understanding around CAR%, it is important that the impact of gender is 
understood in different age-ranges. This is important as it is known that women develop CAD 
later than men, but that this is associated with increased severity (147). This may be as a result 
of a loss of the protective effects of estrogen on endothelial function (147). The protective effects 
of hormone replacement therapy have also been previously demonstrated. Although this is not 
known (220). 
A third limitation is both of these studies is the use of a controlled breathing protocol, rather 
than using a isocapnic CPT protocol. It has been recently demonstrated that hypocapnia has a 
profound effect on carotid artery diameter and is therefore a significant confounding variable 
(221). In this study, as well as in other studies, a controlled breathing protocol was undertaken 
where participants are coached to breathe normally throughout the research protocol. However 
Tymko et al (2017) recently demonstrated that the common carotid artery dilated to a greater 
extent during isocapnic (controlled CO2) CPT when compared to poikilocapnic (uncontrolled CO2) 
CPT (221). They suggest that this is as a result of the common carotid arteries inherent sensitivity 
to CO2. This highlights a potential confounding variable within the project as well as other 
projects measuring carotid artery response to the CPT. This is discussed further within the “future 
work” chapter of this thesis.  
A fourth limitation is the lack of research in to the effects of prehypertensive and hypertensive 
participants. In study one, we attempted to recruit pre-hypertensive and hypertensive 
participants to investigate the relationship between central artery endothelial function and 
hypertension. This is important as there is a correlation between peripheral arterial endothelial 
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function and hypertension (222, 223) and chronic hypertension may be at least in part as a result 
of loss of peripheral vascular function. Hypertension is also common in CAD and CABG patients 
(224).  
A fifth limitation is a lack of understanding the effect smoking has on endothelial function in both 
clinical groups and healthy participants. It has previously been demonstrated that smoking 
negatively effects endothelial function (225). The smoking status of participants was therefore 
recorded prior to testing for each study. This was recording in study one using a health style 
questionnaire and in study two using the patients’ medical records. In study one, none of the 
participants admitted to smoking. In study two, the smoking status and pack years was recorded. 
However, as there was a limited number of participants, sub-group analysis including smoker’s 
vs non-smokers could not be undertaken. This is a limitation of these studies and the effect of 
smoking on CAR% in both healthy participants and in patients undergoing CABG surgery is a 
potential confounding variable and needs further investigation.  
7.4. Physiology of CAR; relation with future work  
Carotid artery vasomotion was measured as a surrogate of endothelial function. Arterial 
vasomotion is regulated by a number of inter-related mechanisms. These can be broadly 
categorized into endothelium-dependent and endothelium-independent mechanisms.  
Endothelium-dependent mechanisms of vasomotion 
Endothelium-dependent mechanisms of vasomotion are controlled by two inter-related systems; 
neuronal and metabolic mechanisms.  
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Neuronal-mediated mechanisms 
The SNS is a key regulator of vascular tone, this was investigated in denervated, and regional 
reinnervated segments of tissue in cardiac transplant patients. There was a larger increase in flow 
in response to sympathetic stimulation in reinnervated tissue when compared to denervated 
tissue. This suggested that adrenergic mechanisms regulated tone to a greater extent than 
metabolic mechanisms during sympathetic stimulation (14). Neuronal regulation occurs through 
a complex competitive relationship between dilatory and constrictive stimuli driven by a- and b- 
adrenoreceptors on the endothelium and tunica media (14). This was reviewed extensively in the 
“background” chapter as well as in Figure 1 in this thesis. The integrity and function of the 
endothelium are both key to a normal dilatory response following SNS stimulus (14). The 
endothelium is the key driver of vasomotion through down-stream control of vascular tone 
through Vascular Smooth Muscle Cells (VSMC’s). Indeed, the loss of integrity and therefore 
function of the endothelium was typified in those at risk of cardiovascular disease and those with 
established CVD (14). The loss of function of the endothelium was identified via abnormal 
truncated responses or paradoxical constriction in response to SNS stimulation including the CPT. 
This constriction response was predictive of risk in cardiovascular disease and cardiovascular 
events in CVD patients (14, 42, 109). This highlights the key role neuronal control plays in 
vasomotion.  
Metabolic-mediated mechanisms 
Metabolic mechanisms also play a crucial stimulus for endothelial-mediated vasomotion. It is 
technically challenging to distinguish metabolic from neuronal mechanisms in-vivo. The 
metabolic regulation of vascular tone has been investigated more thoroughly in cardiac tissue 
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than in cerebral blood flow (CBF). A local increase in myocardial metabolism leads to a decrease 
in microvascular resistance, which causes an increase in coronary blood flow to meet the 
increased metabolic demand. In response to the increase in blood flow, the elevation in shear-
stress drives eNOS expression and further SMC-mediated vasodilation. Krivokapich et al (1989) 
demonstrated that a 2.8-fold increase in myocardial work was associated with a 2.2-fold increase 
in myocardial perfusion. Importantly, the same group demonstrated a requirement-to-perfusion 
mismatch in patients with CAD (138).  This pattern has been duplicated in a subsequent study by 
the same group (138, 226). This was extensively reviewed within the “Background” section of this 
thesis. Metabolic-mediated vasomotion is likely to also play a role in cerebrovascular 
vasomotion, particularly via the carotid arteries. However, the extent to which metabolic drive 
controls carotid artery vasomotion is unknown.  
The partial pressure of CO2 has been investigated as a surrogate of cerebral metabolism and 
driver of SS. Changes in end-tidal CO2 have been demonstrated to be potent stimulants for intra- 
and extra-cranial vasomotion (227, 228). This increase in end tidal CO2 was related to dose-
dependent changes in carotid artery diameter, likely driven through SS (145).  
This highlighted cerebral perfusion’s sensitivity to changes in the partial pressure of arterial blood 
CO2 (PaCO2). An increased PaCO2 (hypercapnia) causes a decrease in cerebrovascular resistance 
and an increase in cerebrovascular blood flow. In contrast, hypocapnia causes an increase in 
cerebrovascular resistance and decreased CBF. In addition, an increased PaCO2 is associated with 
a shear-stress mediated carotid artery dilation (145). Tymho et al (2017) investigated the effect 
of CO2 on carotid artery response to the CPT. They found that the common carotid artery dilated 
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to a greater extent during an isocapnic CPT (controlled CO2) when compared to a poikilocapnic 
CPT (uncontrolled CO2) (221). They suggest that the mechanism may be due to an inherent 
sensitivity of the common carotid artery (CCA) to a reduction in partial pressure of end-tidal CO2 
(PetCO2) which resulted in an attenuation in blood flow and/or SS response during poikilocapnic 
CPT (221). This represented a key potential driver of CAR% throughout the CPT. However, end-
tidal CO2 (PetCO2) was not controlled for in our studies. The participants were provided clear 
breathing instructions and no participants appeared to have hyperventilated throughout testing. 
This was in accordance with previously published research (49, 54, 229). It is therefore unlikely 
that PaCO2 significantly contributed to the CAR% in either of our studies. However, the impact of 
PaCO2 and therefore SS however remains a potential confounding variable when measuring 
CAR%. The requirement for a dynamic end-tidal forcing (DEF) system required for controlling 
PaCO2 would limit the use of the CAR% test to research laboratories or specially designed clinical 
rooms, rather than the point-of-care testing portable ultrasound would allow. A study 
investigating the impact of a controlled breathing protocol (54, 130, 229) vs dynamic end tidal 
forcing-controlled (221) PaCO2 is key. This would identify the best method to control SS-mediated 
vasomotion and allow researchers to control this as a potential confounding variable.   
The CPT was also associated with a significant increase in blood pressure (BP) which may have 
affected CAR% (230). This increase in blood pressure lead to an increased SS and transmural 
pressure. This increase is a potential significant driver of response to CPT. We therefore 
investigated the relationship between CAR% and the blood pressure response in healthy 
individuals. We found that the carotid artery diameter response precedes that of the BP 
response, that there was no correlation between CAR% and BP response, and that there were 
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comparable BP responses in participants who “dilate” and “constrict” in response to the CPT  
(130). Taken together, this provides evidence that CAR% was not significantly driven by the 
increase in BP associated with the CPT. Although it is technically challenging to investigate CAR% 
in the absence of a blood pressure response. Monahan et al (2013) used a- and b-adrenoreceptor 
agonists to blunt BP response to the CPT. They found this also abolished vasomotion in the LAD 
in response to the CPT (139). Similarly, Van Mil et al (2018) reported a-adrenoreceptor blockade 
blunted BP response and abolished carotid and coronary artery response to the CPT. This 
highlighted the technical difficulty in investigating CAR% in the absence of a BP response as both 
BP response and CAR% are adrenoreceptor-dependent (139).  
The fact that reinnervated cardiac segments (neuronal and metabolic mechanisms) dilated to a 
greater degree than de-innervated segments (metabolic mechanisms only). Taken together with 
the fact that adrenoreceptor blockade abolished carotid and coronary artery vasomotion in 
response to the CPT suggests neuronal mechanisms are key to vasomotion. Our study suggested 
that the increase in BP (and therefore SS) associated with the CPT was not a significant driver of 
CAR%. This added further weight to the theory that CAR% is predominantly endothelial-driven 
regulated by neuronal mechanisms. However, the profound effect metabolic mechanisms have 
on carotid artery vasomotion suggest that this may have been a key contributor to CAR%, 
particularly in hypocapniac CPT.  This remains a key potential confounding variable and therefore 
requires further investigation before CAR% can be used clinically. The precise impact both 
neuronal and metabolic mechanisms have on CAR% remain technically challenging to elucidate.  
Endothelium-independent vasomotion 
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The ability of VSMC’s to dilate is a key component of vasomotion down-stream of the 
endothelium. Therefore, the vasodilatory response was reliant upon both an intact and 
functional endothelium as well as arterial responsiveness to Nitric Oxide (NO). Nitroglycerin acts 
as an endothelium-independent NO donor, and nitroglycerin-induced vasodilation (NID) is used 
as a measure of endothelium-independent vasodilation. A reduction in endothelium-
independent vasodilation has been demonstrated in patients at increased risk of CVD (42, 231, 
232) as well as in healthy aging (82, 233). NID has been shown to be impaired in participants with 
cardiovascular risk factors indicating VSMC dysfunction (234, 235). Importantly NID dysfunction 
was associated with a higher incidence of cardiovascular events and has been used as a 
prognostic marker in clinical groups (234, 235). This highlighted the importance of endothelium-
independent vasodilation in CAD. The mechanisms by which endothelium-independent 
vasodilation are inhibited in cardiovascular disease can be separated into structural and 
functional alterations.  
Structural Alterations  
The structural alterations affect vasomotion up-stream of a normally functioning endothelium. 
This is associated with an increase in the connective tissue matrix associated with an increased 
intima-medial thickness (IMT). This may limit relaxation and increase proliferation of VSMC’s 
which causes a relative decrease in NO availability derived from nitroglycerin (236). This 
increased IMT is thought to be as a result of progressive calcification, elastic fibre degeneration 
and increased collagen content alongside VSCM proliferation (237). This results in an increased 
rigidity within the artery and reduced vasomotion independent of a functioning endothelium. 
This is supported by clinical studies which have shown that an increased IMT is associated with 
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cardiovascular risk and poorer outcomes (238-240). However, IMT was not measured in this 
study. It was difficult to maintain the lines of Pignoli (IMT visualized using ultrasound) whilst 
scanning in this group. This was due to the practical challenges of scanning overweight 
participants. In study two, 40 participants were overweight (BMI 25-30) and 39 were obese (BMI 
30+). This study investigated carotid artery function, rather than structure. A consistent ROI was 
therefore selected rather than prioritising maintaining the lines of Pignoli. It was not possible to 
identify patients with an increased IMT and therefore altered structure. A number of studies have 
demonstrated an inverse correlation between IMT and vascular function including brachial (38, 
157, 241) and femoral arteries (157, 242, 243). Studies which investigated the relationship 
between carotid IMT and function via FMD have demonstrated mixed results. Some studies have 
found an inverse correlation between IMT and function, whereas others have demonstrated a 
positive correlation (244-248). This may be as a result of variances in methodology including 
artery used in the FMD and population group. In future studies, IMT could be measured in all 
participants allowing a relatively simple measure of carotid artery structure. This would also 
identify patients with increased IMT and therefore structural alterations which may affect CAR% 
in the context of a normally functioning endothelium.  
Functional Alterations 
As well as alterations in vascular structure, there are also alterations in VSMC (endothelium-
independent) function associated with CVD risk. Although the mechanisms for developing 
endothelial-independent dysfunction aren’t fully understood, The impact of an increased ROS on 
VSMC’s has been highlighted. This increased ROS was associated with hypertension, 
hyperglycemia, hypercholesterolemia and CVD have been postulated as a source (14, 236). The 
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increased ROS inhibited NO production thereby inhibiting VSMC function (endothelium-
independent mechanism). This also inhibited soluble guanyl cyclase (sGC) and cyclic guanosine 
monophosphate (cGMP)-dependent kinases thereby inhibiting VSMC relaxation and 
consequently vasodilation in the context of a normally functioning endothelium (236). Similarly, 
increased ROS attenuated the biotransformation of nitroglycerin by inhibiting mitochondrial 
aldehyde dehydrogenase (ALDH) activity thereby further reducing NO uptake. The net result is 
an impaired endothelium-independent (VSMC-mediated) vasodilation in the context of a 
normally functioning endothelium. This would result in an abnormal truncated CAR% response 
with a healthy, functioning endothelium. Endothelium-independent dysfunction has been shown 
to be associated with cardiovascular risk, and independently predictive of outcomes in 
cardiovascular disease patients (42, 235, 249). This demonstrates the importance of 
endothelium-independent factors affecting carotid artery vasomotion. This further 
demonstrates the importance of endothelium-independent mechanisms on vascular health. 
Maruhashi et al (2018) suggests that endothelial function cannot be accurately measured from 
vasomotion alone (236). They suggest that endothelial function has to be interpreted in the 
context of endothelium-independent nitroglycerin-induced dilation (NID). They further suggest 
that, if there are both impaired endothelium-dependent and endothelium-independent 
vasomotion. It may be impossible to discern whether the impaired vasodilatory response is as a 
result of endothelial dysfunction alone or concurrent abnormalities in both. This highlights the 
importance of measuring NID in CAR%. The impact of sublingual glycerol trinitrate (GTN – a NO 
donor) on carotid artery reactivity has previously been investigated in healthy participants. 
Thijssen et al (2011)  found that GTN caused both carotid artery and femoral artery dilation in 
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both old and young participants (250). They demonstrate the safety and feasibility of using GTN 
to investigate carotid artery NID. Similarly, GTN administration has been demonstrated to be safe 
in both patients with CVD and carotid artery disease (251). This was not feasible within this study 
as the research was undertaken by a non-clinician. This therefore highlights the key role 
endothelium-independent dilation plays in driving vasomotion and also highlights the safety and 
efficacy of using sublingual GTN to measure carotid artery NID. However, our group have 
demonstrated previously that CAR% is correlated with CVD risk and predicts AEs in PAD patients 
without measuring NID (54, 111).  
Taken together, the impact of endothelium-independent vasodilation highlights a key future area 
for research. This requires further research investigating the impact both carotid artery 
endothelium-dependent and -independent mechanisms have on risk in CABG surgery. In such a 
study, participants would first undergo the CPT to investigate endothelium-dependent 
vasomotion. They would then undergo carotid artery diameter testing alongside sublingual GTN 
with a sufficient wash-out period after the CPT. The combination would allow researchers to 
investigate the impact of endothelium-dependent, and -independent dysfunction on patient 
outcomes. It may be that mild dysfunction in either endothelial-dependent or -independent 
mechanisms are compensated for via the subsequent mechanism. The presence of two inter-
related mechanisms affecting carotid artery dilation may also explain the variance in response 
seen in this study as well as others. This variance may be due to the degree of (dys)function as 
well as the presence or absence of compensatory mechanisms. 
7.5. Future Work (Scan Acquisition and Analysis) 
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A further area for potential development is advancement in scan acquisition and analysis. During 
the process of undertaking this PhD, another group have published extensively on the utilisation 
of 3D tomographic ultrasound in imaging vessels in 3D (252-254). This is a technology that may 
be used to gain a more complete measure of carotid artery vasomotion. This also offers an 
opportunity to undertake a more complex analysis of vasomotion using response curve analysis 
to better capture complex vasomotor responses.  
Tomographic 3D Ultrasound 
When the carotid artery is investigated using ultrasound, a segment of artery is imaged along a 
single 2D plane. The carotid artery response is estimated by measuring the distance between 
proximal and distal walls of the artery along a single plane (Figure 16). This is used as a surrogate 
measure of arterial diameter. However, this is associated with two key limitations. Vasomotion 
is a complex response associated with circumferential squeezing/relaxation throughout the 
diameter of the vessel. This results in a change in vessel lumen volume. Whereas, current 2D 
techniques measure the distance between arterial walls. The uniformity of vasomotion and the 
resultant change in arterial diameter in response to the CPT has not been investigated. A loss of 
mechanical stability which resulted in non-uniform vasomotion has been demonstrated 
previously in bovine carotid arteries and has been measured using computational modelling  
(255, 256). This is termed “arterial buckling” and has been demonstrated in response to 
hypertensive pressure, reduced axial stretch or changes in wall stiffness and dimension (255, 
256). The contraction of arteries resulting in tortuous phenotypes associated with age and CVD 
risk are also associated with non-uniform vasomotion (255, 257). This is represented in Figure 16 
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below.  It is not known to what extent carotid arteries suffer arterial buckling or non-uniform 
vasomotion throughout the CPT. There is also an increased risk of buckling in tortuous arteries 
(257).  It may therefore be more accurate to measure change in lumen volume rather than wall 
distance as a measure of vasomotion.   
 
Figure 16) A diagrammatic representation of the vascular response throughout the three phases 
of the CPT. Including the “baseline”, “vasodilation” phase through SNS stimulation and the 
“recovery” phase. A) A normal dilation phase in which both proximal and distal walls dilate 
equally throughout the vasodilation phase and B) A non-uniform dilation phase in which the 
distal wall moves to a greater extent than the proximal wall.  
As arteries are 3D structures, it is difficult to capture an in-focus artery along the entire segment 
of vessel along a single plane. This is particularly difficult as arterial tortuosity increases with age 
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and CVD risk factors such as hypertension and diabetes mellitus (Figure 17) (258). This therefore 
forces practitioners to concentrate on a limited section of in-focus artery further limiting the size 
of segment analysed throughout the CPT. The use of 3D tomographic ultrasound may offer a 
relatively simple method to produce 3D reconstructed maps of vasomotion. In 3D tomographic 
ultrasound, a specifically designed ultrasound probe is used to take a series of transverse images 
throughout a segment of the vessel. These images are then used alongside software to create a 
geometric mesh (253). This can be used to create computational models of vessel volume. Feurer 
et al (2012) demonstrated that tomographic ultrasound is an accurate and reliable method to 
measure both carotid artery volume and plaque structure. They also demonstrated its potential 
use in identifying high-risk plaque (210). Similarly, Ball et al (2018) recently demonstrated that 
3D tomographic ultrasound can be used to calculate both vessel and plaque volume in patients 
with both symptomatic and asymptomatic carotid artery stenosis (252). The same group have 
also validated the use of contrast-enhanced 3D tomographic ultrasound in patients with PAD 
(254). They further report that tomographic ultrasound performed better than B-Mode 
ultrasound, CT and MR imaging when calculating volume measurements of an ex vivo phantom 
model of porcine arteries (253). Taken together, this highlights the potential use for 3D 
tomographic ultrasound to non-invasively measure the volume of carotid arteries in 3D. This may 
overcome potential limitations of current 2D methodologies including non-uniform vasomotion 
and an inability to measure a vessel along a single plane. This may also add to the accuracy of 
ultrasound as a measure of vasomotion. To our knowledge, there are currently no studies that 
have investigated the use of tomographic ultrasound to measure carotid artery reactivity. This 
 170 
may be due to the inherent difficulties in capturing dynamic changes through time in a 3D 
structure.  
 
Figure 17) A diagrammatic representation of the process of vascular ultrasound using B-mode 2D 
ultrasound. A) A normal straight artery in which all areas of the inner wall of both the proximal 
and distal aspects of the artery are within the area of maximum resolution and B) A tortuous 
artery in which the proximal aspect of the inner wall are partially outside the area of maximum 
resolution producing sub-optimal scan resolution.  
Response Curve Analysis 
A second limitation may be in image analysis. CAR% is the maximum change in diameter 
described as a percentage above or below baseline. Although this is a valid measure of change in 
diameter and has been previously demonstrated to predict risk in PAD patients (54), this may be 
an over-simplification of the complex response which occurs throughout the CPT. In particular, 
some participants demonstrated an initial small dilation followed by constriction. The 
physiological impact of this and the impact on patient outcomes is currently unknown. Similarly, 
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it is unknown to what extent “delayed” response is a marker of endothelial dysfunction. A 
delayed response has also been correlated with increased cardiovascular risk (111). This may 
mean that it takes a larger stimulus (and therefore a relatively longer time spent in the CPT) to 
reach a threshold to cause dilation due to the reduced expression of pro-dilatory 
adrenoreceptors. Van Mil et al (2017) demonstrated a significant reduction in peak response 
(CAR%), total response (CARauc) and diameter at 90 seconds (CAR90) in young (24±3) vs old 
participants (61±8). They also found a reduction in CAR% (P: 0.060), CARAUC (P:0.034) and CAR90 
(P:0.037) in participants with the presence of CVD risk factors compared to healthy individuals 
(111). Similarly, Buckley et al (2018) found CAR% and CARAUC were significantly correlated to CVD 
risk factors (229). Taken together, these studies demonstrated that peak response, diameter 
response and timing are significantly delayed in older participants and those at an increased CVD 
risk (111, 229). This highlights key characteristics associated with the CPT response, which were 
not captured when calculating peak CAR% alone. As the diameter was recorded continuously 
throughout the CPT, there may be an opportunity to perform response curve analysis. This may 
allow the creation of a set of healthy reference values incorporating known differences in 
physiological response to the CPT associated with both gender (221, 259) and age (260). A 
goodness-of-fit analysis can then be investigated to analyse divergence from healthy references 
values. This can be used to identify patients with an abnormal vasomotion response to the CPT 
and may capture abnormal response characteristics such as “mixed” initial dilation followed by a 
constriction or delayed response time currently not captured using CAR%. These response 
characteristics have been associated with CVD risk and may also be additional markers of 
dysfunction.   
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7.6. Future Work (Practical Considerations) 
The current techniques used to investigate CAR% were associated with two practical 
considerations or areas for potential development.  
 A key practical consideration is the use of hand-held probes in ultrasound. Free-hand duplex 
ultrasound is current clinical practice used in real-time to image and characterize 
(patho)physiology (261, 262). This is highly dependent upon the practitioner and does not require 
standardization for reproducibility. As this is not used to measure a dynamic response, this is not 
as dependent upon a standardized static baseline. In the CPT, as participants moved to place 
their hand in water, one of the risks was movement of the probe. This would result in a shift from 
baseline or artefacts in the trace which were subsequently removed prior to analysis (54, 130). 
To avoid this, physiological landmarks were identified prior to recording and used as reference 
points (49). The use of mechanical probe-holding devices has been investigated in the context of 
Flow Mediated Dilation (49). The use of probe-holding devices has been associated with an 
increased FMD reproducibility (263). However, another group demonstrated that probe-holding 
devices did not improve reproducibility when scanning was performed by experienced 
practitioners who adhere to strict guidelines (264). Although these guidelines were developed 
for FMD, they can be broadly applied to CAR%. However, there are no current expert consensus 
guidelines for CAR%. Taken together, standardization and an ability to avoid artefacts and 
movement whilst scanning is key. This is particularly important when trying to quantify 
vasomotion. To our knowledge there are currently no publications addressing the reliability or 
reproducibility of CAR% in clinical groups. Importantly, CAR% has been demonstrated to have 
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good same-day and next-day reproducibility in healthy participants (115). There are also 
currently no consensus guidelines on the use of CAR% or accepted requirements to be considered 
proficient. The use of standardized guidelines along-side mechanical probe-holding devices may 
reduce the considerable time taken to become proficient and may also improve reliability in 
already proficient researchers. This may be a key step in translating CAR% from the research 
laboratory into clinical practice. 
A further practical consideration relates to the time-consuming nature of analysis. If a measure 
of endothelial function is going to be used in clinical practice. It is key that it can be used as a 
real-time read-out of endothelial function. The results should also be produced quickly and 
simply to aid real-time clinical decision making. When calculating CAR%, all analysis was 
performed offline. A ROI was manually drawn, and automated wall tracking software was used 
to calculate diameter. Ten second intervals were manually drawn for the entire CPT and the 
average diameter calculated for each ten second bin. This was then input in to a pre-coded excel 
spreadsheet and CAR% is calculated (14, 54, 130). In 3D ultrasound, segmentation algorithms are 
used, and slice volume is then calculated slice-by-slice. This is again time-consuming and would 
also require additional manual statistical analysis. If these techniques are going to be 
implemented into clinical practice, this requires significant automation. Image analysis has vastly 
benefitted from automated wall-tracking software (49). However, the further automation of 
identifying a ROI in 2D analysis and vessel segmentation in 3D analysis is key. The improved 
resolution of current-generation and next-generation ultrasound machines mean greater 
contrast in vessel wall (lines of Pignoli) vs surrounding tissue. This along-side improvements in 
wall-tracking software means improved axial resolution and distinct arterial wall borders. This 
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results in a greater potential for automated generation of an ROI or vessel segmentation 
algorithms (49). The use of artificial intelligence may be able to “train” algorithms to 
automatically select an ROI or segment a vessel, accounting for variance in angle of 
insonation/vessel and then calculate vasomotion dynamically throughout the CPT. A key 
limitation in current automated analysis and segmentation is in the presence of scanning 
artefacts. Physiological artefacts such as calcification and increased IMT/atheroma pose a 
considerable problem and lead to incorrect analysis (265). This along-side procedural artefacts 
such as movement throughout the CPT, participant swallowing, movement during breathing or 
arterial pulsatility remain a barrier to automation. It may be possible to “train” artificial 
intelligence algorithms to manage or avoid these artefacts alongside the use of 
electrocardiogram-gated (ECG) analysis to minimize the impact of carotid artery pulsatility (49).  
The subsequent automation of statistical analysis is relatively simple, requiring an automated 
work-flow including macros which deposit the raw data in to a pre-coded spreadsheet. This can 
then automatically calculate variables such as peak response. Similarly, pre-coded spreadsheets 
have been developed for automated FMD analysis (266). Taken together, the potential 
improvements in 3D scan acquisition and analysis may be of clinical benefit. However, the 
complex and user-dependent nature of sonography along-side the laborious nature of image 
preparation and analysis make this unlikely to be integrated into clinical practice currently. The 
development of specialist guidelines along-side the use of mechanical probe-holding devices may 
reduce the significant training required. The development of automated analysis workflows and 
algorithms will further reduce the time-burden and are required before this tool can be used 
more widely in a research setting and in clinical practice.   
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A key consideration when implementing any technology in to clinical practice is the cost of this 
technology. The cost is associated with the initial cost of equipment and subsequent upkeep, the 
time in which the test takes and the level of expertise required to undertake the test. In this 
study, the initial set-up is relatively inexpensive. The most expensive part is the ultrasound 
machine used. Although each unit is expensive, ultrasound machines are common within 
hospitals. Although the initial scan is not time-consuming and only takes approximately four 
minutes, the post-recording processing and analysis is time-consuming. It is therefore key that 
this is expedited as outlined above. It is also time-consuming to develop the relevant expertise in 
carotid artery ultrasound. These scans are typically undertaken by highly trained clinical 
practitioners. The use of probe-holding devices may again reduce the training time required to 
become proficient. This will again further reduce the cost associated with utilizing carotid artery 
ultrasound clinically.  
7.7. Thesis Conclusions  
Study Conclusions  
The over-arching aim of this thesis was to investigate the use of the CAR% to non-invasively 
measure endothelial function and to investigate if this predicts risk in patients undergoing CABG 
surgery. This thesis was separated in to two distinct but inter-linked studies. First a mechanistic 
study which investigated the mechanistic regulation of CAR%. Second, a clinical study which 
investigated the predictive capacity of CAR% in CABG patients.  
In study one, we demonstrated that CAR% is not significantly driven by the increase in BP 
throughout the cold pressor test. This study, together with the literature suggests that CAR% is 
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predominantly driven by neuronal mechanisms. This adds weight to the validity of CAR% as a 
surrogate measure of endothelial function and therefore vascular health. In study two, the 
impact of CAR% was investigated in coronary artery disease patients. There was a weak inverse 
correlation between CAR% and EuroSCORE II (p: 0.0114 r: -2.85). This suggested that participants 
at the highest surgical risk (EuroSCORE II) also had the poorest endothelial function. This adds 
some weight to the validity of using CAR% as a measure of systemic vascular health. EuroSCORE 
II alone did not predict AEs in this group (p: 0.60). CAR% alone did not predict AEs in this group 
(p:0.51). This may be as a result of the low incidence of AE’s in this study. When combined, CAR% 
marginally improved the ROCauc in multivariable analysis. This may be suggestive of an 
improvement. Although this was still not predictive (r:0.60 vs 0.615). Although this study is 
unable to conclusively investigate if CAR% predicts risk in CABG patients. To our knowledge, this 
is the first study investigating the ability of CAR% to predict risk either alone or combined with 
EuroSCORE II in central arterial disease patients.  
This thesis, together with the literature adds further validity to the use of CAR% as a research 
tool. It may add some evidence to the usefulness of CAR% as a tool to predict risk when combined 
with EuroSCORE II. Although results remain inclusive. It further highlights a number of key areas 
which may further improve the validity and accuracy of CAR% as a measure of endothelial 
function. These improvements together with a larger sample size and therefore higher incident 
number would be required to conclusively investigate if CAR% improves the predictive ability of 
EuroSCORE II.   
Clinical Implications 
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Endothelial function has been demonstrated to be independently predictive of risk in 
cardiovascular disease groups. EuroSCORE II performs more poorly in the highest, and lowest risk 
patients. This makes clinical decision making in these group more difficult. We provided some 
evidence that CAR% may offer a simple method to measure endothelial function as a surrogate 
of vascular health. We also provide some limited evidence that CAR% may improve the predictive 
capacity of EuroSCORE II, although this was inconclusive. The identification of endothelial 
dysfunction and therefore poor vascular health may help clinical decision making in “borderline” 
patients who are candidates for both CABG surgery and conservative medical treatments as well 
as those at the highest surgical risk. Importantly, the identification of endothelial dysfunction 
could identify a potential target for treatment. This would allow endothelial dysfunction to be 
improved prior to surgery thereby reducing their risk.  
The ability to accurately predict risk is key in clinical decision making as well as in providing 
patients with the most accurate information possible to allow them to make an informed choice 
about their care. The risk of any surgical procedure is dependent upon a large number of both 
modifiable and non-modifiable factors. It is therefore key to approach risk prediction holistically 
rather than as a “one size fits all” approach. It is important to encompass the largest number of 
factors possible which are known to impact outcomes within a specified clinical group. The 
EUROSCORE II tool encompasses a large number of factors and allows clinicians to offer a more 
personalised approach to risk prediction. In line with part 2 of the PROGRESS framework, 
EuroSCORE II encompasses a large dataset and can be modified to encapsulate differences in 
demographics such as age and gender. It is also easily calculable and importantly can be readily 
updated. These factors facilitate the continued usefulness of EuroSCORE II, particularly the ability 
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to update these tools to include new and emerging predictive factors. If CAR% is going to be 
included in future updated risk prediction tools it is key that, this is easily incorporated in to 
current and future risk predict tools, that it is derived from large and diverse datasets, that it can 
be easily and reliably performed in a clinical setting and that the results are robust. As with all 
risk stratification tools, it is also key that there remains an ability to further update and modify 
this tool as information emerges. CAR% has previously been demonstrated to be reliable. The 
process of capturing and analysing CAR% can be expedited as described in the “future work” 
section of this chapter. The process of undertaking and analysing CAR% is easily modifiable and 
therefore can be easily updated as more information is garnered and improvements are made to 
both the workflow and analysis of CAR%. This makes CAR% relatively simplistic to incorporate in 
to clinical practice.  
Incorporating endothelial function into clinical practice 
As discussed above, measures of endothelial function have a potential benefit in risk prediction 
in CABG surgery. We provided some evidence that CAR% may marginally improve the predictive 
capacity of EuroSCORE II. Although this was not definitive and therefore further studies including 
larger studies involving more participants and therefore AEs. If future studies further 
demonstrate the usefulness of CAR%, it may be implemented into clinical practice. This is reliant 
upon the development of specific guidelines to standardize testing alongside the implementation 
of probe-holding tools to reduce training time and improve inter-user reliability in less 
experienced practitioners. This should be developed along-side tools and workflows that 
automate and expedite image processing and analysis. The standardization of image acquisition 
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along-side automated analysis would allow the creation of a large database of reference values. 
This would include healthy individuals incorporating differences in endothelial function 
associated with age and sex. The creation of a set of standardized healthy reference values would 
allow practitioners to compare an individual’s response to these reference values using 
goodness-of-fit analysis to identify endothelial dysfunction. The presence or absence of 
endothelial dysfunction can be used as a binary measure that can be incorporated into current 
risk stratification tools.  The current risk stratification tools include variables that are known to 
affect endothelial function. However, they do not measure endothelial function. They simply 
note the presence of factors which negatively affect endothelial function and use that to predict 
risk. They do not include atheroprotective factors, such as exercise, or measure the net impact, 
of both atheroprotective and atheroprone factors have on endothelial function. This may be a 
significant flaw.  The carotid artery response may be uniquely placed to offer a simple and non-
invasive method to measure and quantify the accumulative effect of both atheroprotective and 
atheroprone risk factors on central artery vascular health. This allows a move away from 
epidemiological risk scores derived from large datasets to a personalized approach to risk 
stratification at the point-of-care.  
The CAR% test may also highlight a key potential therapeutic target to optimize at-risk patients 
prior to surgery. Endothelial-dependent coronary artery vasodilation has been improved using a 
variety of pharmacological interventions including angiotensin-converting-enzyme inhibitors, b-
hydroxymethylglutaryl-coenzyme A reductase inhibitors and antioxidants (267-270). Importantly 
Buckley et al (2019) recently demonstrated a 12-week exercise intervention reversed endothelial 
dysfunction and restored endothelial function in participants at an increased risk of 
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cardiovascular disease measured using CAR% (229). Similarly, Hambrecht et al (2000) also 
demonstrated that a 4-week intensive exercise intervention reversed coronary artery endothelial 
dysfunction in patients with coronary atherosclerosis (271). They measured coronary artery 
endothelial function using quantitative angiography in response to acetylcholine. Taken 
together, this highlights two key benefits of measuring CAR%. First, identifying patients who have 
endothelial dysfunction and who are therefore at an increased risk. Second, undertaking both 
pharmacological and non-pharmacological lifestyle interventions in these groups. Thereby 
improving endothelial dysfunction or reversing dysfunction prior to surgery. This includes 
reducing modifiable risk factors and undertaking exercise-interventions to reverse endothelial 
dysfunction. These interventions in the form of “pre-habilitation” may be used to improve 
endothelial function or reverse endothelial dysfunction and therefore reduce risk prior to 
surgery. A growing body of research demonstrates the benefits of “pre-habilitation” to optimize 
patients prior to cardiac surgery (272). These interventions have improved intensive care unit 
(ICU) discharge times, shortened length of stay, improved cardiovascular fitness, and reduced 
complications in CABG patients (272). There is currently no consensus on optimum intervention 
types. It is not known to what degree these benefits of “pre-hab” are as a result of improved 
exercise tolerance or improvements in endothelial function. It is possible these benefits are as a 
result of improved endothelial function/reversal of endothelial dysfunction. To our knowledge, 
there are no studies investigating the degree to which the known benefits of “pre-hab” are as a 
result of improved endothelial function alongside classical exercise benefits such as improved 
cardiovascular fitness. The simplicity and non-invasive nature of carotid artery reactivity would 
allow serial measurements to be taken throughout an intervention at the point-of-care, such as 
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in the community or GP practice. The development of strict guidelines alongside automation 
would allow non-experts to undertake testing and produce an immediate read-out of endothelial 
function. This would allow clinicians to monitor the improvement in endothelial function in 
response to an intervention and adapt it appropriately. Thereby offering a personalized approach 
to risk assessment and patient optimization prior to surgery. It is hoped that pre-surgical 
optimization including improving endothelial function in patients with endothelial dysfunction 
would then translate in to improved outcomes and lower incidences of adverse events in patients 
undergoing CABG surgery.  
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Appendices 
7.8. Appendix 1 – Search Strategy 
A comprehensive and methodological search strategy is key to an effective and accurate 
literature review. I therefore employed a PICO framework.  
Population Cardiovascular disease 
Intervention/Indicator Endothelial Function 
Comparison Measures of Endothelial Function 
Outcome Vascular Health OR Cardiovascular Disease 
Outcomes 
 
Table 21) A PICO table describing the search framework used as part of the search strategy. 
I first began by trying to understand the current literature of risk stratification/prediction tools 
on cardiovascular disease. I therefore combined “Cardiovascular Disease”, “Cardiovascular 
Event”, “AE”, and “Death” together with “endothelial function” and “Endothelial dysfunction”. 
This highlighted a broad range of methods employed within the literature to measure risk in 
cardiovascular disease. I then differentiated methodologies by “invasive” and “non-invasive” 
techniques used to measure endothelial function. This was in both the context of cardiovascular 
disease and in healthy populations.  I moved more specifically on to non-invasive measures of 
endothelial function, combining this with “cardiovascular disease”. As the carotid artery was used 
as a surrogate measure of coronary artery endothelial function. I then began to look specifically 
at measures of endothelial function within the carotid artery, together with coronary arteries. As 
this study uses the Cold Pressor Test (CPT) as a SNS stimulus, I looked specifically at measures of 
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endothelial function in response to the cold pressor test. This is a relatively small field, with a 
small number of very active researchers. I therefore began to use citation tracking to gain a better 
understanding of the field. Although the use of the CPT in endothelial function and risk prediction 
is a relatively small field. The CPT had been used extensively in physiology studies investigating 
systemic and vascular responses to the CPT.  
Critical Literature Review 
I performed a comprehensive critical review of the literature. The primary sources were Medline 
Plus, Pubmed via the National Centre for Biotechnology Information (NCBI). This identified 526 
studies related to the research area, of which 87 were relevant to my research. I accepted 64 
studies, of which 17 were methodological, 30 investigated endothelial function, 5 
epidemiological and 15 risk prediction.  Of the 30 studies investigating endothelial function, the 
most important papers are firstly (33) describing endothelial function. The seminal paper by 
Dunker et al first described a potential mechanism by which endothelial function is lost in 
atherosclerosis and cardiovascular disease using specific a- and b-adrenoreceptor inhibition 
(273).  The importance of endothelial function has been demonstrated in a number of pre-
diseased and diseased states including in patients with moderate and advanced cardiovascular 
disease. Throughout the literature review, I found that there were a number of techniques that 
had been used to investigate endothelial function. Within the literature, there are 17 articles 
directly or indirectly investigating endothelial function as a method to predict risk in cardiac 
populations. These can be broadly divided in to “direct” methods which investigate endothelial 
function within the coronary arteries and “indirect” which measure a surrogate of coronary 
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artery endothelial function. Schachinger et al first investigated the prognostic ability of 
endothelial function (42). They directly investigated coronary artery endothelial function using 
intracoronary infusion of Ach and the cold pressor test alongside coronary angiography. 
Importantly Hays et al confirmed this (53). Due to the expensive and invasive nature of direct 
coronary artery endothelial function measurement, indirect methods were subsequently 
developed. The most completely researched method of indirectly measuring coronary artery 
endothelial function is using Flow Mediated Dilatation (FMD) (64). Although FMD has been 
researched extensively, there are significant limitations when using peripheral arteries as 
surrogate measures of central artery endothelial function. Experiments within our group 
demonstrated that the carotid artery endothelial function correlates with coronary artery 
endothelial function. It was also demonstrated by others that the carotid artery is more similar 
to the coronary artery in both structure and function. Most importantly, others within our group 
demonstrated that the carotid artery response (CAR) to the cold pressor test measured non-
invasively using carotid artery ultrasound predicts risk in patients with PAD (54). We therefore 
hypothesized that carotid artery response to the cold pressor test and measured non-invasively 
using carotid artery ultrasound predicts risk in patients with significant coronary artery disease 
undergoing coronary artery bypass graft surgery.  
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Figure 18)) A Prisma diagram of the available literature on coronary artery endothelial function 
and endothelial function in risk prediction.  
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7.9. Appendix 2 – Study 2 Scatterplots 
The scatterplots below are produced during the analysis of study 2. These can be used to visually 
inspect the spread of the data.  
This panel demonstrates the whole-group demographic data of participants included in study 2.  
 
Figure 19) Scatterplots of Age, Sex, CCS score and NYHA score. Participants in grey had post-
operative AEs.  
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The relationship between CAR% and BMI was then investigated. This was investigated both as a 
continuous variable and when participants are grouped according to NHS guidelines for BMI. 
 
 
Figure 20) Scatterplots of CAR% vs BMI. A) A correlation of CAR% vs BMI in this group. There 
appears to be a number of “clusters”. B) CAR% in participants when grouped according to their 
BMI group according to NHS guidelines for BMI. Grey datapoints are those who had AEs. Black 




The relationship between CAR% and CVD risk factors was then investigated.  
 
 
Figure 21) Scatterplots of Family History and Risk factors for developing cardiovascular disease 




The relationship between CAR% and markers of disease severity was then investigated.  
 
Figure 22) Scatterplots of markers of disease severity. Grey datapoints are those who had AEs. 
Black datapoints had no AEs.  
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